






















































































































































































The	 endoscopic	 approach	 to	 the	 skull	 base	 has	 revolutionised	 surgery	 in	 this	 region.	
Neurosurgery	involves	working	around	anatomical	structures	that	are	uniquely	sensitive	to	
damage	 and	 manipulation	 and	 patients	 may	 be	 left	 with	 the	 potentially	 devastating	
consequences	of	violating	these	structures.	The	endoscope	allows	the	surgeon	to	visualise	
and	 reach	 areas	 that	 were	 previously	 only	 accessible	 with	 large	 amounts	 of	 destructive	






critical	 structures.	Damage	 to	 these,	or	diminution	of	blood	 flow	 through	 them,	 results	 in	
profound	neurological	dysfunction	or	death.		
	
The	 rate	 of	 damage	 to	 the	 carotid	 artery	 with	 these	 approaches	 ranges	 from	 1.1-9%	
depending	on	 the	 specific	 approach	and	pathology.	 The	 carotid	 artery	 in	 this	 region	does	
not	generally	lend	itself	to	suturing,	clipping	or	direct	closure	methods.	Currently,	the	gold	
standard	for	repair	is	the	application	of	crushed	muscle	patch	to	stop	the	bleeding	and	seal	











To	 demonstrate	 the	 use	 of	 fibrin/thrombin/gelatin	 patches,	 fibrin/thrombin	 glues,	
beta-chitosan	 patches	 and	 self-assembling	 peptides	 on	 a	 sheep	 model	 of	 carotid	
artery	haemorrhage	and	quantify	the	rate	of	pseudoaneurysm	formation.	
	




To	 quantify	 the	 stress	 response	 in	 surgeons	 training	 on	 this	 sheep	 vascular	
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The	 skull	 base	 refers	 to	 the	 floor	 of	 the	 cranial	 cavity	 and	 forms	 a	 complex	 boundary	
between	the	brain	and	facial	structures(1).	It	is	conventionally	described	as	comprising	the	
ethmoid,	 sphenoid,	 occipital,	 frontal,	 and	 temporal	 bones(2).	 From	 a	 neurosurgical	
perspective,	 it	 is	one	of	the	most	challenging	anatomical	areas	to	operate	on.	There	are	a	
number	of	 crucial	 vascular	 and	neural	 structures	which	pass	 through	 the	 skull	 base	or	 lie	




There	 are	 a	 huge	 variety	 of	 pathologies	 that	 occur	 within	 the	 skull	 base.	 These	 include	
tumours	of	the	brain	parenchyma	and	pituitary	gland,	tumours	of	nerves	and	nerve	sheaths,	
tumours	 of	 dural	 origin	 and	 affixation,	 aneurysms	 of	 blood	 vessels,	 carotid-cavernous	
fistulae,	 traumatic	 fractures,	 &	 cerebrospinal	 fluid	 leaks	 –	 both	 spontaneous	 and	
traumatic(4-8).	 There	 are	 also	 multiple	 pathologies	 that	 occur	 within	 the	 pneumatised	
paranasal	 sinuses	 of	 the	 frontal,	 sphenoid,	 and	 ethmoid	 bones.	 The	 primary	 surgical	
challenge	 for	 the	 majority	 of	 these	 lesions	 is	 gaining	 access	 to	 the	 pathology	 without	
damaging	surrounding	structures(9).		
	
Neurosurgeons	 and	 Otolaryngologists	 have	 long	 collaborated	 in	 designing	 approaches	 to	
this	area	however	 the	concept	of	accessing	 the	cranial	 cavity	via	 the	nose	has	existed	 for	





remove	 the	 cranial	 contents	 for	 embalming	 purposes(10-13).	 From	 the	 point	 of	 view	 of	
surgical	 practice,	 the	 trans-nasal	 approach	 was	 explored	 in	 the	 1890s	 by	 Giordano	 on	
cadavers.	In	1907,	Schloffer	described	using	this	approach	to		successfully	debulk	a	pituitary	
tumour(14).	 Results	 from	 transcranial	 approaches	 appeared	 superior	 however,	 and	
mainstream	 practice	 favoured	 transcranial	 approaches	 until	 Guiot	 demonstrated	 both	
efficacy	and	safety	of	the	endoscope	in	the	1960s(5).	His	work	described	the	first	attempts	





first	neuro-endoscopy	multi-specialty	 teams	being	 formed	 in	 the	1990s(5,	15).	Endoscopic	
surgery	 has	 subsequently	 become	 a	 valuable	 tool	 for	 accessing	 the	 anterior,	middle,	 and	
posterior	cranial	fossae	and	even	the	odontoid	process	region(16-21).	It	can	be	a	minimally	
invasive	technique	leaving	few	to	no	external	scars	and	with	potentially	less	requirement	to	
mobilise	 intracranial	 structures	 and	 retract	 brain	 to	 access	 pathology(22).	 This	 does	 not	
mean	 that	 the	 approach	 is	 without	morbidity,	 merely	 that	 the	 set	 of	 risks	 and	 potential	
morbidities	 	 have	 changed(22).	 The	 technique	 requires	 knowledge	 of	 where	 anatomical	













challenge.	 The	 ideal	 approach	 would	 use	 the	 shortest	 and	 most	 direct	 route	 to	 the	
pathology,	 with	 the	minimum	 of	 anatomical	 disruption.	 This,	 however,	 is	 rarely	 possible.	
Approaches	 must	 therefore	 be	 tailored	 to	 the	 patient’s	 anatomy	 to	 provide	 access	 and	
visualisation	 but	 to	 avoid	 potentially	 irreversible	 damage	 to	 the	 sensitive	 neural	 and	
vascular	 structures	 that	 course	 through	 these	 areas.	 In	 situations	 where	 an	 anatomical	
corridor	is	not	immediately	accessible,	the	usual	route	is	to	remove	bony	prominences	and	






structures	 such	 as	 the	 internal	 carotid	 artery(ICA),	 greater	 and	 lesser	 superficial	 petrosal	
nerves,	 oculomotor,	 trochlear	 and	 abducens	nerves	 that	 run	 in	 close	proximity	 to,	 and	 in	
some	 cases	 through	 these	 bony	 areas.	 Given	 that	 bony	 structures	 are	 essentially	
incompressible	and	dural	 reflections	can	only	be	manipulated	to	a	small	degree,	surgeons	
have	developed	strategies	 to	 increase	their	access	and	visualisation.	Key	amongst	 these	 is	
the	draining	of	cerebrospinal	fluid	(CSF).	There	is	between	75	and	150ml	of	CSF	within	the	
combined	 cranial	 cavity	 and	 spinal	 subarachnoid	 space.	 Drainage	 or	 diversion	 of	 CSF	 can	
significantly	 improve	 the	 ability	 to	 manipulate	 brain	 parenchyma	 in	 order	 to	 visualise	
pathology	 and	 aid	 dissection.	 This	 may	 be	 achieved	 through	 either	 the	 pre-operative	
placement	 of	 a	 lumbar	 drain	 with	 judicious	 release	 of	 CSF	 if	 the	 situation	 allows	 or	 the	
opening	of	 arachnoid	 planes	within	 the	basal	 cisterns	 and	 subsequent	 gentle	 suction	 and	
drainage(25-27).		
	
The	 skull	 base	 surgeon	 is	 also	 constrained	 by	 the	 ability	 to	 position	 the	 patient	 to	
adequately	 access	 these	 areas.	 Optimum	 positioning	 for	 visualisation	 may	 cause	
compression	of	venous	channels	with	impedance	of	blood	return,	engorgement	of	deep	and	
superficial	veins	and	raised	 intracranial	pressure	(ICP)(28).	This	may	also	 increase	bleeding	
and	hinder	 visualisation	 of	 the	 operative	 field.	 Surgery	may	occur	 near	 venous	 sinuses.	 If	
these	are	 torn	and	air	allowed	 to	enter,	an	air	embolism	may	 result	with	potentially	 fatal	
results.	The	range	of	mobility	of	the	patient’s	neck	may	pose	a	difficulty	in	positioning	and	
allowing	efficient	and	comfortable	surgical	corridors	to	be	created.	The	surgeon’s	hands	and	
line	of	site	along	the	microscope’s	 field	of	view	should	align	 in	such	a	way	as	 to	allow	for	
protracted	operating	times.	If	the	surgeon	has	to	hold	him	or	herself	in	an	uncomfortable	or	








and	exacerbated	 some	of	 these	problems.	 The	direct	 approach,	 generally	 using	 loupes	or	
microscope	 for	 magnification,	 has	 the	 advantage	 of	 providing	 the	 surgeon	 with	 a	 3-
dimensional	 field	of	 view	and,	 from	a	 kinesiology	perspective,	 allows	 the	 surgeon’s	hand-





Intraoperative	 images	 –	 Endoscopy	 vs.	 Microscopy	 of	 approach	 to	 the	 pituitary.	 The	
endoscopic	view	is	panoramic.	The	microscopic	view	is	impeded	by	instruments(18)	
	






The	endoscope	has	 the	drawback	of	 (until	 the	very	 recent	addition	of	 the	3D	endoscope)	
providing	a	2-dimensional	picture	to	the	surgeon	however	it	does	allow	the	surgeon	to	‘look	
around	 corners’	 with	 angled	 scopes,	 removing	 the	 need	 for	 a	 direct	 line	 of	 site.	 It	 also	
provides	a	source	of	illumination	at	the	tip	of	the	scope	and,	with	the	ever-improving	quality	
of	 lenses	 and	 cameras,	 a	 high	 definition	 view	 of	 the	 operative	 area(30,	 31).	 Endoscopic	




the	 endoscope	may	 be	 introduced	 through	 natural	 anatomical	 points	 of	 access	 –	 i.e.	 the	



















or	 even	 improved	 with	 endoscopic	 approaches	 compared	 to	 traditional	 open	








computer	which	 triangulates	 the	 patient’s	 skull,	 a	 fixed	 reference	 point	 on	 the	 operating	
table,	and	a	camera	affixed	to	the	computer(41).	Through	the	pre-operative	registration	of	
the	 patient’s	 surface	 anatomy	 to	 either	 computerised	 tomography	 (CT)	 and/or	 magnetic	
resonance	 imaging	(MRI)	scans,	surgeons	can	acquire	a	real-time	view	of	where	his	or	her	








pituitary	 region	 is	 achieved	 through	 the	 sphenoid	 sinus.	 The	 endoscope	 is	 introduced	
through	the	nostril	and	advanced	to	the	back	of	the	nasal	cavity.	If	the	surgeon	has	concerns	
regarding	the	possibility	of	CSF	 leak,	they	may	raise	a	mucosal	septal	flap	on	an	inferiorly-
based	 vascular	 pedicle.	 The	 sphenoid	 ostia	 are	 then	 identified	 and	 enlarged	 before	
removing	 their	 entire	 anterior	 wall,	 intersinus	 septum	 and	 the	 vomer.	 The	 endoscope	 is	
further	 advanced	 to	 visualise	 the	 posterior	wall	 of	 the	 sphenoid	 sinus	 and	 the	 important	










Relationship	 of	 cavernous	 sinuses	 and	 carotid	 artery	 to	 sphenoid	 sinus	 in	 cadaveric	 study	
(Rhoton)(44)	
	
The	 cavernous	 sinuses	are	paired	venous	 structures	 that	 lie	 lateral	 to	 the	 sphenoid	 sinus.	
They	are	contained	within	a	dural	envelope.	They	receive	venous	blood	from	the	superior	
and	 inferior	 ophthalmic	 veins,	 superficial	 cortical	 veins,	 the	 sphenoparietal	 sinus	 and	 the	
superficial	middle	 cerebral	 veins.	They	drain	via	 the	 superior	and	 inferior	petrosal	 sinuses	













and	the	view	of	 the	sella	 (S)	beyond	with	 the	 internal	carotid	arteries	 (ICA)	 laterally	 in	 the	





















Within	each	 cavernous	 sinus	 is	 the	 cavernous	 segment	of	 the	 internal	 carotid	artery(ICA).	









the	 tentorial	 artery	 of	 Bernasconi	 and	 Cassinari	 (supplying	 the	 tentorium,	 occulomotor	
nerve	and	 trochlear	nerve)	and	 the	dorsal	meningeal	artery,	 suppling	 the	abducens	nerve	
and	 clivus(2,	 64).	 The	 inferolateral	 trunk	 is	 the	 more	 distal	 and	 divests	 from	 the	 parent	
























cerebral	 artery	 (MCA)	 to	 supply	 brain	 parenchyma	 (the	 anterior	 circulation)(67).	 In	 up	 to	








posterior	cerebral	artery	 (PCA)	 is	also	 fed	from	this	anterior	circulation	and	 is	 thus	also	at	
risk	of	infarction	in	an	ICA	occlusion(72).		
	





The	 second	 major	 area	 of	 vascular	 concern	 in	 extended	 endoscopic	 neurosurgical	
procedures	 is	 the	 anterior	 cerebral	 artery	 (ACA)	 complex.	 The	 ICA	 gives	 off	 an	 anterior	











A1	 across	 the	 anterior	 communicating	 artery.	 This	 is	 known	 as	 an	 azygous	 ACA.	 The	
recurrent	 artery	 of	 Huebner	 is	 a	 small	 feeding	 artery	 to	 the	 caudate	 nucleus	 and	
anteroinferior	internal	capsule	that	comes	of	the	distal	A1	or	proximal	A2.	Disruption	to	its	
flow	may	give	the	patient	contralateral	spastic	hemiparesis	and	sensory	loss(75).	Endoscopic	
approaches	 to	 the	 floor	of	 the	anterior	 cranial	 fossa	and	 the	planum	sphenoidale	 require	
drilling	 and	 tissue	dissection	directly	under	 this	 complex.	 	 The	ACAs	and	 their	 perforating	
branches	 supply	 eloquent	 cortex	 and	 every	 effort	 is	 made	 to	 preserve	 the	 vessels.	
Dissection	 is	 complicated	 by	 the	 fact	 that	 anterior	 skull	 base	 pathology	 such	 as	 planum	
sphenoidale	 and	 tuberculum	 sella	 meningiomas	 often	 shift	 the	 anterior	 cerebral	 arteries	
from	their	usual	anatomical	position(73,	76,	77).	Careful	attention	must	be	paid	to	the	pre-












Endoscopic,	 endonasal	 view	 of	 the	 suprachiasmatic	 cisternal	 region	 post	 resection	 of	
tuberculum	 sellae	 meningioma	 (GR:Gyrus	 Recti;	 ON:	 Optic	 nerve;	 A1:	 Pre-communicating	
segment	 of	 the	 anterior	 cerebral	 artery;	 A2:	 Post-communicating	 segment	 of	 the	 anterior	







The	 posterior	 circulation	may	 also	 be	 encountered	 in	 endoscopic	 skull	 base	 surgery.	 The	
paired	vertebral	arteries	enter	the	cervical	spine	at	the	C6	level	in	the	majority	of	patients.	
They	travel	superiorly	 through	the	 foramen	transversarium,	 lateral	 to	 the	spinal	cord,	and	
then	 loop	 posteriorly	 and	 then	 anteriorly	 over	 C1	 to	 enter	 to	 skull	 through	 the	 foramen	
magnum.	They	give	off	a	posterior	 inferior	cerebellar	artery	(PICA)	and	then	unite	to	form	
the	basilar	artery	(BA),	which	is	generally	at	approximately	the	level	of	the	ponto-medullary	
junction(2,	79,	80).	The	anterior	 spinal	artery	 is	given	off	at	 this	point	and	 runs	down	 the	
anterior	aspect	of	 the	spinal	cord	 in	 the	midline.	The	BA	 then	runs	 in	 roughly	 the	midline	
plane	(but	can	deviate	significantly	to	either	side)	up	the	anterior	aspect	of	the	brainstem,	
gives	off	the	anterior	inferior	cerebellar	arteries	(AICA)	and	the	superior	cerebellar	arteries	














to	 remove	pannus	 from	anterior	 to	 the	 spinal	 cord	 in	 the	 case	of	 arthritic	 conditions	and	
instability(18).	Again,	the	caveats	to	endoscopic	approaches	apply	–	these	are	primarily	for	


















Cerebral	 digital	 subtraction	 angiogram	 demonstrating	 4mm	 right	 distal	 basilar	 perforator	









complete	occlusion	 is	usually	 fatal	or	severely	disabling(83).	Bleeding	may	also	occur	 from	












of	 disruption	 of	 its	 vascular	 supply.	 This	 is	 most	 commonly	 due	 to	 focal	 embolism	 or	
thrombus	but	may	also	occur	as	a	result	of	global	hypoperfusion	and	hypotension(86,	87).	It	
makes	 up	 2%	 of	 the	 adult	 human	 body	 weight	 but	 receives	 25%	 of	 cardiac	 output	 and	









In	theory,	acute	unilateral	 ICA	blood	flow	disruption	should	result	 in	contralateral	 ICA	and	
VA	flow	reaching	the	hemispheres	through	the	circle	of	Willis(91).	In	practice,	however,	this	
is	highly	variable.	Techniques	to	control	haemorrhage	in	endoscopic	skull	base	surgery	must	
take	 this	 factor	 into	 account	 and	 maintain	 patency	 of	 flow	 through	 the	 ICA	 as	 much	 as	
possible.	 The	 evidence	 from	 neurosurgical	 literature	 regarding	 the	 temporary	 proximal	
clipping	of	 feeding	vessels	 indicates	that	 interruption	to	the	blood	supply	of	<3	minutes	 is	




perfusion,	however	 longer	 times	 risk	permanent	neuron	and	astrocyte	death(92-94).	Care	
should	 also	 be	 taken	when	 extrapolating	 this	 data	 to	 entire	 anterior	 circulation	 or	whole	
hemisphere	models	which	would	 occur	with	 sudden,	 complete	 ICA	 occlusion.	 The	 risk	 of	
cerebral	 ischaemia	 or	 infarction	 post	 sacrifice	 of	 the	 carotid	 artery	 is	 difficult	 to	 quantify	
however	 even	 in	 patients	 who	 have	 passed	 a	 balloon	 occlusion	 test	 (where	 a	 balloon	 is	
inflated	 in	 the	 carotid	 artery	 to	 occlude	 flow,	 the	 patient	 kept	 awake	 and	monitored	 for	
neurological	change),	rates	of	neurological	injury	can	be	as	high	as	4.8%(95-97).	This	injury	
may	not	be	 immediately	 apparent	and	 there	 is	 a	 risk	of	ongoing	development	of	delayed	
cerebral	 ischaemia	 of	 1.4%	 per	 year(98).	 In	 open	 cranial	 surgery	 for	 aneurysm	 or	 extra-
cranial/intracranial	bypass,	temporary	clips	may	be	applied	to	the	parent	artery	proximal	to	
the	 aneurysm	 to	 allow	manipulation	 of	 the	 fundus	 and	 dissection	 around	 the	 aneurysm	
neck(80,	 99).	 This	 temporary	 clipping	 is	 tolerated	 to	 varying	 degrees	 depending	 on	 a	
number	 of	 factors	 including	 collateral	 circulation,	 systemic	 blood	 pressure	 and	 blood	
rheology.	 In	some	instances,	 ischaemia	and	infarction	may	occur(100,	101).	Woertgen	and	
colleagues	performed	an	audit	on	292	patients	treated	for	aneurysm.	29%	demonstrated	an	
ischaemic	 lesion	on	CT	post-operatively.	 58%	of	 these	patients	had	undergone	 temporary	












factors	 or	 ‘slices’	 lining	up	 to	potentially	 contribute	 to,	 not	 just	 bleeding	 in	 this	 area,	 but	
increasing	 the	 difficulty	 in	 stopping	 it	 once	 it	 occurs(102-105).	 The	 skull	 base	 is	 an	
anatomically	constrained	area	with	brain	parenchyma,	neural	and	vascular	structures,	bony	
prominences	 and	 canals,	 acute	 angles	 and	 dural	 reflections	 all	 existing	 within	 a	 few	
millimetres	of	each	other.	In	addition	to	this,	there	are	a	wide	range	of	pathologies	that	can	
occur	 in	 this	 area.	 These	 include	 neural	 tumours,	 nerve-sheath	 tumours,	 dural-based	
tumours,	bony	skull	 lesions,	cavernous	sinus	 lesions,	and,	 importantly,	vascular	aneurysms	
and	malformations	 given	 the	 location	 under	 the	 brain	 of	 the	 circle	 of	Willis(6-8,	 29,	 102-
114).		
	




endoscope	 lens	 must	 remain	 free	 of	 blood	 to	 avoid	 the	 surgeon	 operating	 ‘blindly’.	 To	
achieve	 this,	 suction	must	be	 introduced	 into	 the	 field	and	 further	 instruments	 to	control	
bleeding	 are	 then	 utilised.	 Space	 and	 angle	 restrictions	 in	 endoscopic	 skull	 base	 surgery	
mean	 suturing	 and	 haemostatic	 clamps	 are	 not	 usually	 a	 realistic	 option.	 It	 is	 also	much	
more	 difficult	 to	 introduce	 traditional	 bipolar	 cautery,	 although	 endoscopic	 skull	 base	








Increasing	 use	 of	 anticoagulant	medications	 including	 aspirin	 (thromboxane	 A2	 inhibitor),	
clopidogrel	 (ADP	 receptor	 inhibitor),	 dabigatran	 (direct	 thrombin	 inhibitor),	 warfarin	
(vitamin	K	carboxylation	inhibitor)	and	apixaban	(GPIIbIIIa	inhibitor)	 in	an	aging	population	
makes	achieving	haemostasis	 even	more	difficult	unless	 these	medications	 can	be	 ceased	
pre-operatively.	This	is	sometimes	difficult	given	comorbid	conditions	and,	occasionally,	the	
requirement	 for	 urgent	 surgery(116).	 In	 addition,	 the	 underlying	 parenchyma	 being	














through	 the	 use	 of	 angled	 scopes,	 also	 extend	 the	 boundaries	 of	 the	 approach	 laterally.	
Couldwell	 et	 al	 &	 Frank	 et	 al	 and	 Gardner	 et	 al	 report	 rates	 of	 5-9%	 in	 series	 of	














requires	 that	 the	 surgeon	be	proactive	 in	 assessing	 the	 likelihood	of	 the	 injury	 occurring.	
Tumours	 that	encase	 the	carotid,	or	are	at	 least	adherent	 in	a	plane	>120	degrees	are	at	
much	higher	 risk	and	these	cases	should	be	discussed	 in	a	multi-disciplinary	meeting	with	
skull-base	 otolaryngologists,	 skull-base	 neurosurgeons,	 radiologists,	 endovascular	
radiologists	&	neurosurgeons	and	ophthalmologists(128).	The	value	of	developing	a	 team-
based	 approach	 to	 skull	 base	 surgery	 cannot	 be	 over-stressed,	 and	 extended	 endonasal	













	It	 is	 important	 to	 review	 the	pre-operative	 imaging	 closely	 to	determine	 if	 there	 are	 any	







or	 dura	 to	 surround	 the	 carotid.	 Even	 if	 present,	 the	wall	 should	not	 be	 considered	 thick	
enough	 to	 protect	 the	 artery	 from	 the	 drill	 or	 other	 instruments(130).	 Bone	windows	 on	
pre-operative	 CT	may	 assist	with	 this	 but	 should	 not	 be	 relied	 on.	 The	 carotids	may	 also	
deviate	 towards	 the	 midline.	 The	 ICA	 are	 usually	 at	 least	 12mm	 apart	 but	 have	 been	
described	as	close	together	as	4mm	in	their	cavernous	segment	and,	rarely,	even	touching	
each	 other(131).	 These	 so	 called	 ‘kissing	 carotids’	 have	 been	 considered	 as	 having	





between	 these	 measured.	 There	 may	 also	 be	 bony	 septations	 and	 spicules	 within	 the	
sphenoid	 and	 cavernous	 sinuses	 which,	 whilst	 not	 dangerous	 in	 themselves,	 may	 either	
require	the	use	of	instrumentation	to	remove,	with	consequent	risk	of	ICA	injury	by	either	
bone	 fragments	 or	 the	 instruments	 used	 to	 remove	 them.	 Cavernous	 segment	 ICA	
aneurysms	make	up	to	12%	of	total	intracranial	aneurysms	in	some	case	series	and	require	
the	 surgeon	 to	 carefully	 plan	 any	endoscopic	 approach(66,	 74,	 96,	 132).	 It	 is	 advisable	 to	
consider	 treating	 these	 prior	 to	 attempting	 any	 endoscopic	 endonasal	 skull	 base	
approaches(133-135).	Rupture	of	 this	 intra-operatively	may	cause	 torrential	bleeding	and,	
potentially,	 the	 development	 of	 a	 carotid-cavernous	 fistula	 (CCF).	 These	 may	 be	 treated	


























has	 previously	 occurred.	 Previous	 radiation	 to	 the	 region	 may	 result	 in	 scarring	 and	
adhesions	 with	 loss	 of	 normal	 tissue	 plans	 and/or	 increased	 friability	 of	 vessels.	
Bromocriptine	therapy	appears	to	increase	the	risk	of	ICA	injury,	possibly	due	to	adhesions	



















Ideally	 factors	 such	 as	 anatomical	 variation	 or	 the	 possibility	 of	 tumour	 erosion	 into	 the	
artery	or	cavernous	sinus	will	have	alerted	the	surgeon	to	the	danger	of	carotid	artery	injury	




must	always	be	alert	 to	the	possibility	of	 injury.	A	pre-operative	briefing	 involving	all	staff	
that	identifies	the	risks	involved	and	the	plan	should	such	an	injury	occur	is	a	highly	valuable	
step.	The	patient	should	always	be	cross	matched	with	compatible	blood	readily	available,	
especially	 in	more	 extended	 endonasal	 approaches.	 Anaesthetic	 staff	 should	 be	 aware	 of	
the	possibility	of	ICA	injury	and	have	a	plan	in	place	in	the	event	that	it	occurs.	Large	bore	IV	
access	 and	 invasive	 arterial	 monitoring	 should	 be	 considered	 prior	 to	 it	 being	 required.	
Neuro-navigation	should	be	utilised	as,	whilst	it	does	not	replace	a	thorough	knowledge	of	

























These	 range	 from	 linear	 incisions	 to	 stellate	or	 large	wall	defects	 caused	by	kerrison-type	
punches	or	high-speed	drill	injury.	Whilst	initial	management	and	resuscitation	is	the	same,	





The	 immediate	 management	 of	 carotid	 artery	 injury	 in	 endoscopic	 surgery	 is	 a	 team-
centered	 approach	 involving	 coordination	 between	 nursing,	 anaesthetic	 and	 surgical	
staff(138).	 Communication	 with	 the	 anaesthetic	 staff	 early	 is	 vital	 and	 they	 should	
immediately	 begin	 volume	 resuscitation	 of	 the	 patient	 before	 their	 haemodynamic	
parameters	 are	 affected.	 It	 is	 important	 to	 maintain	 normotension	 or	 even	 mild	
hypertension	 to	 maintain	 cerebral	 perfusion	 despite	 the	 temptation	 to	 lower	 the	 blood	
pressure	to	assist	haemostasis.	Theatre	staff	should	check	the	suction	to	ensure	that	the	bag	
isn’t	becoming	 full	which	may	 lead	to	a	stoppage	of	suction	when	most	 required.	Theatre	
staff	should	also	activate	the	on-call	angiography	team.		
	
ICA	 injury	 is	much	 easier	 to	manage	with	 a	 2	 surgeon,	 4	 hands	 approach.	 Consideration	





thigh.	 Visualisation	 is	 key	 to	 management	 and	 the	 endoscope	 lens	 must	 remain	 free	 of	
blood.	To	achieve	 this,	 suction	must	be	 introduced	 into	 the	 field,	generally	down	the	side	
closest	 to	 the	 bleeding	with	 the	 endoscope	 introduced	 down	 the	 opposite	 nostril	 to	 just	
proximal	 to	 the	 posterior	 septal	 edge,	 allowing	 it	 to	 be	 used	 as	 a	 shield	 from	 the	 blood	
jet(143,	144).	The	sucker	is	used	to	direct	the	flow	of	blood	away	from	the	lens.	The	second	
sucker	should	be	placed	adjacent	to	the	endoscope	to	ensure	it	is	kept	clear	of	blood.	This	
can	 then	 be	moved	 in	 further	 to	 hover	 over	 the	 bleed	 point.	 It	 is	 obvious	 that	 the	 two-
surgeon	 technique	 is	 of	 great	 help	 in	 this	 situation	 and	 planning	 the	 approach	 such	 that	




Once	visualisation	has	been	achieved,	pressure	 can	be	applied	 to	 the	bleeding	point	with	
patties,	gauze	or	surgical	snow(Ethicon)	as	a	temporising	measure.	It	is	tempting	to	pack	the	
entire	nasopharynx	in	an	attempt	to	stop	the	bleeding	but	this	should	be	avoided	as	much	




unilateral	 ICA	blood	 flow	disruption	should	 result	 in	contralateral	 ICA	and	vertebral	artery	
flow	 reaching	 the	 hemispheres	 through	 the	 circle	 of	 Willis.	 In	 practice,	 however,	 this	 is	
highly	variable.	Techniques	 to	control	haemorrhage	 in	endoscopic	skull	base	surgery	must	
take	 this	 factor	 into	 account	 and	 maintain	 patency	 of	 flow	 through	 the	 ICA	 as	 much	 as	




clipping	of	 feeding	vessels	 indicates	that	 interruption	to	the	blood	supply	of	<3	minutes	 is	
generally	well	 tolerated	with	 the	 brain	 likely	 deriving	 oxygen	 and	 glucose	 from	 collateral	
perfusion	 however	 longer	 times	 risk	 permanent	 neuron	 and	 astrocyte	 death(92-94).	 Care	





Traditionally,	1	 to	2cm3	of	muscle	has	been	harvested	 from	the	abdomen	or	 thigh.	This	 is	




the	 high	 flow	within	 the	 lumen	maintains	 patency	 of	 the	 parent	 vessel(145).	 No	 attempt	
should	be	made	 to	 remove	 the	muscle	once	haemostasis	has	been	achieved.	 This	muscle	
patch	should	be	reinforced	with	a	previously	raised	septal	flap	if	the	carotid	is	in	the	nasal	
cavity	and	covered	with	oxidised	cellulose	and	fibrin	glue	if	intracranial(128).	Nasal	packing	
may	then	be	placed	however	 it	 is	 important	that	this	 is	not	packed	too	tightly	as	this	may	











closure	may	be	attempted.	This	 is	usually	more	applicable	 for	 linear	 injuries.	Padhye	et	al	














work	 for	 smaller	bleeds,	 there	 is	 the	 risk	of	 the	cautery	device	becoming	adherent	 to	 the	
bleeding	 vessel	 with	 subsequent	 tearing	 when	 attempts	 are	 made	 to	 remove	 the	













If	 haemostasis	 is	 not	 able	 to	 be	 achieved	 with	 these	 methods,	 then	 endovascular	
intervention	 may	 be	 urgently	 required	 to	 occlude	 the	 ICA(146).	 It	 is	 important	 that	

















on	 emergence	 and	 extubation,	 which	 may	 potentially	 cause	 the	 patch	 to	 ‘blow	 off’	 the	
vessel.	 The	 surgeon	 should	 attend	 the	 initial	 formal	 angiogram	 to	 determine	 if	 the	 ICA	 is	
patent,	 especially	 if	 large	 amounts	 of	 nasal	 packing	 has	 been	 left	 in	 situ.	 If	 this	 is	 ‘over-
packed’	 the	 patient	may	 need	 some	 of	 this	 removed	 to	 allow	 distal	 flow	 in	 the	 ICA.	 It	 is	
important	 to	note	 that	whilst	we	have	discussed	 the	obvious	and	 immediate	 ICA	bleed,	a	
smaller,	 unrecognised	 injury	 may	 occur	 and	 manifest	 in	 the	 weeks	 or	 months	 following	
surgery(148).		
	
The	 decision	 to	 extubate	 the	 patient	 depends	 on	 whether	 any	 vascular	 anomaly	 is	
discovered	at	the	initial	post-operative	angiogram.	If	none	is	discovered	then	a	reasonable	
option	 is	 to	 wake	 the	 patient	 slowly	 in	 ICU,	 avoiding	 blood	 pressure	 fluctuations	 and	
ensuring	 cerebral	 perfusion	 is	 maintained.	 Sylvester	 et	 al	 performed	 a	 retrospective	









If	an	arterial	wall	 injury	such	as	a	dissection	flap	 is	seen	on	formal	angiogram,	 it	 is	safe	to	
assume	 that	 the	 intima	has	 been	disrupted	with	potential	 for	 thrombosis	 to	 occur.	 Some	
authors	advocate	intravenous	heparin	administration	at	the	time	of	injury(138).	Much	of	the	
rationale	behind	this	has	been	extrapolated	from	stroke	literature	which	does	tend	to	limit	
external	 validity	when	applying	 this	data	 to	 the	 ICA	 injury	patient	population.	The	CADISS	
trial,	 designed	 to	 determine	 the	 optimal	 treatment	 for	 carotid	 dissection	 was	 unable	 to	
make	 a	 recommendation	 regarding	 whether	 antiplatelet	 agents	 or	 anticoagulant	 agents	














There	 are	 three	 layers	 to	 the	 carotid	 artery.	 The	 tunica	 intima,	 the	 tunica	media	 and	 the	








occur	 in	 an	 injury	 during	 endoscopic	 surgery,	 blood	 escapes	 until	 the	 surgeon	 is	 able	 to	
apply	pressure	to	the	wound	and	close	the	defect.	The	anastoclip	and	primary	closure	with	





Evidence	 for	 the	 pathophysiological	 mechanism	 of	 this	 is	 extrapolated	 from	
histopathological	studies	of	spontaneous	and	traumatic	carotid	dissections(155).	Blood	may	
track	 between	 the	 intima	 and	 media	 layers	 and	 generate	 a	 false	 lumen.	 Pulsatile	 flow	
peaking	 at	 systolic	 pressures	 may	 force	 blood	 along	 this	 neo-layer.	 This	 may	 eventually	
thrombose	 or	may	 rupture	 out	 into	 the	 surrounding	 tissues.	 In	 arteries	 where	 there	 are	
branch	 vessels,	 the	 dissection	may	 occlude	 the	 take-off	 of	 these	 vessels	 and	 cause	 distal	
ischaemia.	This	propagation	is	usually	anterograde	but	may	occur	in	a	retrograde	fashion	as	
well(156).	 Thrombosis	 of	 the	 aneurysm	 is	 not	 benign.	 The	 thrombosis	 may	 cause	























H&E	 of	 pseudoaneurysm	 in	 Fresian	 horse	 demonstrating	 fibrosis,	 fat	 and	 inflammatory	
monocyte	infiltration(159).		
	
H&E	 stain	 of	 pseudoaneurysm	 in	 Fresian	 horse	 demonstrating	 disorganised	 collagen	
fibres(159)	
	
Histology	 and	 immunohistochemistry	 studies	 have	 been	 performed	 to	 determine	 the	
precise	 sequence	 of	 events	 in	 arterial	 wall	 remodelling	 and	 healing(160).	 Bauriedel	 et	 al	
used	a	rat	carotid	artery	model	of	injury	to	show	the	changes	that	occur	at	0,	4,	24,	and	48	
hours	and	4,	7,	14,	and	28	days	post	injury.	Their	experiment	was	designed	to	delineate	the	
exact	 cells	 involved	 to	 determine	 if	 these	 could	 be	 inhibited	 to	 prevent	 stent	 thrombosis	
post	angioplasty.	Rats	underwent	a	balloon	angioplasty	to	damage	the	endothelium	of	the	
vessel	wall.	6	rats	were	then	sacrificed	at	each	time	point	and	their	artery	wall	examined.	













The	putative	mechanism	of	development	 is	damage	 to	 the	vessel	 in	 the	 initial	phase	with	




common	 aetiology	 worldwide	 is	 in	 penetrating	 cranial	 trauma	 such	 as	 stabbing	 or	
shrapnel/bullet	 wounds	 and	 the	 majority	 of	 the	 literature	 supporting	 treatment	 is	
extrapolated	 from	 this(165,	 166).	 Post	 ICA	 injury,	 it	 is	 generally	 considered	 that	 the	
incidence	of	subsequent	pseudoaneurysm	development	is	in	the	order	of	10-35%	however	
some	 series	 report	 up	 to	 66%(7,	 111,	 121,	 125).	 This	 is	 partly	 a	 function	 of	 the	 low	 case	




the	 literature	 from	 1975-2010(167).	 Intraoperative	 arterial	 haemorrhage	 occurred	 in	 17	






64	 days	 for	 those	 with	 intraoperative	 haemorrhage	 and	 83	 days	 for	 those	 without.	 The	
mortality	 rate	 was	 9%	 with	 one	 patient	 dying	 of	 epistaxis	 and	 another	 of	 intracranial	
hypertension	day	1	post	stenting(167).	Treatment	mechanism	was	heterogeneous	as	would	
be	 expected	 for	 a	 pooled	 case	 series	 over	 such	 a	 long	 time	 frame	 and	 ranged	 from	
conservative	 management,	 stenting,	 coiling,	 microsurgical	 clipping	 and	 complete	 carotid	
occlusion	 (41%	 of	 patients).	 The	 authors	 of	 this	 review	 advocate	 weekly	MRI/MRA	 post-
operatively	in	the	event	of	carotid	injury	for	4	weeks	with	monthly	MRI/MRA	post	this(167).	
The	Adelaide	experience	has	been	to	obtain	a	formal	angiogram	on	the	day	of	injury,	which	
is	 then	 repeated	 at	 1	week	 post-operatively	 and	 then	 again	 at	 6	weeks	 and	 1	 year	 post-
















The	 treatment	 of	 pseudoaneurysm	 is	 dependent	 on	 size,	 location,	 and	 whether	 it	 has	
ruptured	prior	to	treatment.	Given	that	even	a	balloon	test	occlusion	cannot	reliable	predict	
an	individual	patient’s	reliance	on	blood	flow	from	a	particular	carotid	artery,	consideration	
should	 be	 given	 to	 preserving	 the	 carotid	 if	 possible(172).	 It	 is	 possible	 to	 perform	 an	
endovascular	 sacrifice	of	 the	 carotid	 artery	by	 completely	 occluding	 it	with	 coils	 however	
this	 leaves	the	patient	at	risk	of	developing	an	 infarction	distal	 to	this(138).	Other	options	
include	coil	occlusion	of	the	pseudoaneurysm	with	or	without	stenting	of	the	parent	vessel	
or	 direct	 open	 repair,	 and	 remodelling	 (although	 this	 is	 generally	 not	 possible	 in	 the	
cavernous	 segment	of	 the	carotid)(122,	148,	156,	157,	169,	170,	173-175).	 It	may	also	be	
possible	 to	 use	 a	 flow	 diverting	 stent	 that	 directs	 flow	 beyond	 the	 pseudoaneurysm	 and	
causes	stasis	and	subsequent	thrombosis	within	the	aneurysm(173,	176).	It	is	important	to	
be	aware	of	the	 location	of	the	ophthalmic	artery	 in	relation	to	the	pseudoaneurysm.	The	
ophthalmic	 typically	 leaves	 the	 ICA	a	 few	millimetres	beyond	any	 injury	 to	 the	 cavernous	





be	 as	 high	 as	 4.5%	 in	 the	 first	 30	 days	 and	 patients	 are	 generally	 treated	 with	 dual	
antiplatelet	agents	(aspirin	and	clopidogrel)	or	similar	agents	which	may	delay	or	preclude	
further	 surgery(134,	 135,	 177-180).	 A	 more	 invasive	 approach	 to	 revascularisation	 is	 an	
extra-cranial	 to	 intracranial	 (EC-IC)	bypass	with	a	conduit	being	 sutured	 from	the	external	












vessels	 however	 diagnosis	 requires	 formal	 angiogram	 and	 demonstration	 of	 early	 venous	






























ICA	 injury	 is	 a	 potentially	 devastating	 complication	 of	 endoscopic	 endonasal	 surgery.	 It	 is	






clearly	 defined	 before	 this	 situation	 is	 encountered.	 The	 muscle	 patch	 is	 certainly	 the	
simplest	and	most	studied	haemostatic	material	utilized	in	this	setting	however	in	the	event	
that	 the	 injury	 is	 able	 to	 be	 both	 visualized	 and	 accessed	 by	 instruments,	 direct	 vessel	
closure	with	AnastoClip	(LeMaitre	vascular)	or	a	curved	T2	aneurysm	clip	may	be	attempted.	
It	 is	 important	 that	whatever	 technique	 is	 used,	 that	 vessel	 lumen	patency	 is	maintained	
and	ongoing	flow	to	allow	distal	perfusion	of	the	brain	occurs.	Endovascular	sacrifice	of	the	
vessel	is	a	last	resort	and	one	that	may	potentially	lead	to	neurological	deficit,	even	if	one	
had	performed	a	balloon	 test	occlusion	previously.	 It	 is	 important	 to	 realize	 that	 stopping	
the	haemorrhage	is	merely	the	first	step	in	the	management	of	these	patients	and	they	will	










Effective	 Coagulation	 and	 subsequent	 haemostasis	 results	 from	 a	 balance	 of	 multiple	
inhibiting	and	facilitating	 factors.	These	 include	the	endothelial	wall	cells	of	blood	vessels,	
platelets,	 leukocytes,	 coagulation	 cascade,	 and	 the	 milieu	 of	 temperature	 and	 blood	










The	 interaction	of	platelets	with	 the	damaged	endothelial	wall	 is	a	key	component	of	 the	
pathophysiology	of	many	atherosclerotic	and	ischaemic	disease	but	it	also	serves	a	valuable	
role	in	haemostasis.	The	normal	platelet	count	is	150-300x109L.	Platelet	life	span	is	generally	
considered	 to	 be	 8-10	 days	 which	 accounts	 for	 the	 usual	 surgical	 practice	 of	 ceasing	





the	 exposed	 and	 damaged	 endothelial	 walls	 that	 activates	 and	 aggregates	 platelets	 and	
allows	 them	 to	 form	 a	 plug.	 Platelets’	 response	 to	 exposure	 to	 activating	 factors	may	 be	




There	 are	 multiple	 methods	 and	 phases	 of	 activation	 but	 the	 most	 prominent	 is	 the	
exposure	of	platelets	to	collagen,	which	is	found	almost	everywhere	in	the	body	apart	from	
the	 inner	 wall	 of	 the	 vascular	 endothelium.	 When	 endothelium	 becomes	 damaged,	 the	









On	 the	 platelet	 membrane	 surface,	 GPIb-IX	 (a	 glycoprotein	 receptor)	 is	 coupled	 to	 the	
platelet	 cytoskeleton	 by	 actin-binding	 protein(192).	When	 GPIb-IX	 is	 exposed	 to	 vascular	
endothelium,	 it	 immediately	attaches	 to	von	Willebrand	 factor	 (vWF),	which	 is	 layered	on	
collagen	 fibres	 in	 the	 damaged	 endothelium.	 Two	 collagen	 receptors,	 GPVI	 and	 GPIIbIIIa	
stablise	 this	 attachment.	 GPIb-IX	 and	 GPVI	 bind	 together	 and	 activate	 GPIIbIIIa	 complex	
which	binds	fibrinogen	and	fibronectin	to	the	damaged	area(192-195).		This	GPIb-IX	binding	












Phases	 of	 the	 mechanisms	 of	 platelet-induced	 haemostasis.	 Platelet	 fibronectin	 (pFn)	 is	







shape	 change	also	 involves	 the	projection	of	pseudopods,	which	 increase	platelet	 surface	
area	for	adhesion.	This	adhesion	is	mediated	by	many	factors(199).	High	levels	of	localised	
extracellular	 calcium	 (Ca+)	 and	 magnesium	 (Mg+)	 ions	 cause	 ‘reversible	 aggregation’	
whereas	 irreversible	 aggregation	occurs	when	 activated	platelets	 release	 arachidonic	 acid	
derivatives	 from	 their	 internal	 membrane	 and	 pro-aggregation	 substances	 such	 as	
adenosine	diphosphate	(ADP),	adenosine	triphosphate	(ATP),	Serotonin	and	Ca+	from	their	









Fibrinogen	 in	 a	 soluble	 glycoprotein	 that	 exists	 in	 blood	 plasma.	 It	 is	 comprised	 of	 three	
polypeptide	 chains.	 It	 is	 cleaved	 into	 fibrin	 by	 the	 action	 of	 thrombin,	 a	 serine	
protease(200).	 Damaged	 cells	 release	 tissue	 factor.	 This	 initiates	 the	 extrinsic	 pathway	 of	
coagulation,	the	end	result	of	which	is	the	development	of	a	cross-linked	fibrin	meshwork	or	
‘clot’	via	thrombin	production.	This	extrinsic	pathway	does	not	result	in	sufficient	thrombin	
in	 and	 of	 itself	 however.	 The	 small	 amounts	 of	 thrombin	 produced	 initially	 cause	
subsequent	 further	activation	of	platelets	and	 triggers	a	 further	 coagulation	pathway,	 the	
intrinsic	pathway.	This	intrinsic	pathway	activation	results	in	the	conversion	of	prothrombin	











As	 more	 becomes	 known	 about	 the	 way	 platelets	 become	 activated	 and	 subsequently	
aggregate,	new	therapeutic	targets	become	available	for	anti-platelet	drug	design.	Common	
agents	 include	 clopidogrel	 (a	 thienopyridine-class	 Adenosine	 Diphosphate	 (ADP)	 receptor	
antagonist),	 aspirin	 (a	 Cyclooxygenase-1	 (COX-1)	 inhibitor)	 and	 Abciximab/Ticagrelor	
(GPIIbIIIa	antagonists)(202).		
	
The	 efficacy	 of	 these	 drugs	 is	 still	 debated	 however	 there	 is	 significant	 evidence	 for	 the	
efficacy	 of	 GPIIbIIIa	 antagonists	 as	 agents	 in	 the	 treatment	 of	 acute	 coronary	 events	 by	








aggregation	 that	 cause	 a	 trend	 towards	 clot	 formation	 by	 the	 coagulation	 pathways.	 The	
intrinsic	 coagulation	 pathway	 is	 potentiated	 by	 membrane	 phospholipids	 released	 from	
platelets.	 This	 leads	 to	 eventual	 thrombin	 formation(189).	 Several	 factors	 expressed	 on	
platelet	 surface	 appear	 to	 play	 a	 role	 in	 preventing	 the	 clot	 from	 being	 broken	 down.	
Platelet	 factor	4	 inhibits	heparin	activity.	P-selectin	 is	a	glycoprotein	usually	 found	only	 in	
granules	 within	 the	 platelet.	 It	 translocates	 to	 the	 platelet	 surface	 when	 the	 platelet	 is	
activated	and	mediates	platelet-leukocyte	interactions	to	include	them	within	the	platelet-
clot	plug.	The	fact	that	P-selectin	is	found	only	on	the	surface	of	activated	platelets	makes	it	







for	markers	of	 activation	and	aggregation,	especially	 if	 these	were	able	 to	be	detected	 in	
peripheral	 blood	 in	 the	 setting	 of	 acute	 coronary	 syndrome	 or	 stoke.	 	 Platelet	 activation	
may	 be	 detected	 by	 a	 change	 in	 shape	 and	 aggregation.	 It	 is	 also	 possible	 to	 measure	




Platelet	 alpha	 granule	 contents	 such	 as	 thromboglobulin	 and	 platelet	 factor-4	 may	 be	
















Monoclonal	 antibodies	 or	 fluorescent	 stains	 are	 utilised	 to	 identify	 and	 detect	 specific	
antigens	 on	 the	 membrane	 of	 activated	 platelets,	 platelet	 membrane-bound	 proteins	
(GPIIbIIIa	 or	 P-selectin)	 or	 shape	 changes	 in	 activated	 platelets(216,	 217).	 GPIIbIIIa	
undergoes	 a	 conformational	 change	 with	 a	 new	 epitope	 formation	 when	 the	 platelet	 is	
activated	 and	 this	 is	 able	 to	 be	 detected	 by	 a	 laser	when	 a	 tagged	monoclonal	 antibody	














to	 aggregate.	 When	 activated,	 it	 undergoes	 a	 conformational	 change	 exposing	 the	
fibrinogen	binding	site(218).	PAC1	antibody	is	able	to	bind	to	this	site	thus	 labelling	active	
platelets	when	 analysed	 via	 flow	 cytometry(216).	 PAC1	 expression	 is	 generally	 decreased	
with	 clopidogrel	 treatment.	 Clopidogrel	 blocks	 the	ADP	 P2Y12	 receptor	 site	 and	 prevents	








P-selectin	 (P-SEL)	 is	 a	 protein	 component	 of	 the	 alpha-granule	 membrane	 of	 resting	
platelets	and	is	only	seen	on	the	platelet	surface	membrane	after	platelet	activation(218).	It	
is	thus	a	marker	of	platelet	degranulation	which	only	occurs	with	platelet	activation.	In	vitro,	











are	 irreplaceable	 in	 terms	 of	 neurological	 control	 of	 human	 functions,	 both	 physical	 and	
cognitive.	 Additionally,	 there	 are	 some	 areas	where	 collateral	 blood	 supply	 is	minimal	 or	
absent	so	sacrifice	of	feeding	vessels	is	a	last	result	as	doing	so	will	result	in	stroke	in	areas	
they	perfuse.	Conventional	methods	such	as	warm	irrigation	for	small	capillary	bleeding	in	
brain	parenchyma,	bipolar	 cautery	 (in	which	bipolar	 electrical	 current	 is	 used	 to	weld	 cut	
ends	of	a	vessel	together),	and	very	gentle	simple	compression	are	suitable	for	open	cranial	
operations	 and	 have	 some	 applicability	 to	 endoscopic	 skull	 base	 surgery.	 Major	
haemorrhage	 is,	 however,	 unlikely	 to	 be	 stopped	with	 such	methods.	 Novel	 agents	 have	
been	 developed	 to	 attempt	 to	 influence	 or	 promote	 various	 parts	 of	 the	 coagulation	
cascade.	These	use	the	pre-existing	natural	pathways	but	insert	foreign	promoters	to	both	
mimic	and	increase	the	local	coagulation	response.	These	products	include	gelatin-thrombin	



















Floseal	 is	 a	 bovine	 gelatin/human-sourced	 thrombin	 combination.	 The	 bovine	 gelatin	 is	




thrombin	 is	derived	 from	plasma	prothrombin	that	 is	 then	mixed	with	calcium	chloride	to	
convert	it	to	thrombin.	These	are	both	sourced	from	within	the	United	States.	This	presents	
a	 small	 but	 real	 risk	 of	 infectious	 disease	 transmission	 despite	 screening.	 This	 includes	
bovine	spongiform	encephalopathy	(BSE	–	a	transmissible	form	of	neurodegenerative	prion	
disease)	however	the	absolute	risk	 is	 likely	to	be	exceedingly	small(223).	There	have	been	






contact	with	 blood	 so	 providing	 a	 localised	 tamponade	 effect.	 From	 the	 point	 of	 view	 of	
coagulation	 activation,	 the	 thrombin	 catalyses	 the	 formation	 of	 a	 fibrin	 clot	 and	 allows	
subsequent	onflow	coagulation	effects.	Excess	matrix	is	removed	with	irrigation	at	the	end	
of	 the	 2	 minutes(225).	 There	 is	 a	 small	 risk	 of	 oedema	 from	 the	 granulomatous	
inflammation	 subsequent	 to	 Floseal	 application	 however	 this	 is	minimized	 by	 removal	 of	
excess	matrix	post	fibrin	clot	formation(226).		
	
Floseal	 does	 not	 require	 the	 presence	 of	 functional	 platelets	 and,	 by	 providing	 topical	
thrombin,	 bypasses	 much	 of	 the	 upstream	 intrinsic	 coagulation	 cascade.	 It	 will	 not,	
however,	work	in	the	presence	of	a	fibrinogen	deficiency(201).	Whilst	Floseal	has	been	used	
since	1999	 in	the	United	States	and	2008	 in	Australia,	 the	majority	of	evidence	for	 its	use	





The	 study	 compared	 Floseal	 with	 a	 gelatin	 sponge	 with	 thrombin	 in	 an	 effort	 to	
demonstrate	equivalent	 results.	Surgeries	were	spread	across	cardiac,	vascular,	 spinal	and	
orthopaedics.	 If	 bleeding	 was	 unable	 to	 be	 controlled	 via	 conventional	 means	 (sutures,	
pressure,	 bipolar	 cautery)	 patients	 were	 randomized	 to	 Floseal	 or	 gelatin	 sponge	 with	
thrombin	 (control).	 Success	 was	 defined	 as	 haemostasis	 at	 10	 minutes	 following	






Floseal	 has	 also	 been	 used	 in	 endoscopic	 nasal/sinus	 surgery.	 Cappabianca	 authored	 a	








Floseal	 is	 used	 extensively	 for	 areas	 of	 bleeding	 within	 the	 brain	 parenchyma.	 Gazzeri	
describes	 a	 neurosurgical	 indication	 for	 floseal	 in	 a	 series	 of	 31	 patients	 with	 primary	
intracerebral	 haemorrhage.	 The	 rationale	 for	 this	 approach	 was	 that	 instead	 of	 a	 wide	
craniotomy	 and	 potentially	 destructive	 corticotomy	 to	 access	 the	 clot	 and	 inspect	 all	
quadrants	 of	 the	 cavity	 to	 ensure	 haemostasis,	 a	 much	 small	 corticotomy	 could	 be	
performed	 if	 Floseal	 was	 then	 used	 to	 fill	 the	 cavity.	 These	 31	 patients	 underwent	
craniotomy	and	evacuation	of	the	intracerebral	clot	with	a	minimally-sized	craniotomy.	The	
cavity	 was	 filled	 with	 Floseal	 for	 3	 minutes	 and	 then	 irrigated	 out	 with	 wash.	 An	 80%	











	It	 does,	however,	 appear	 important	 to	 remove	as	much	of	 the	excess	 Floseal	 as	possible	













gelatin	 has	 also	 been	 observed	 to	 be	 a	 nidus	 for	 infection	 and	may	 potentiate	 bacterial	
growth.	 The	 gelatin/thrombin	 has,	 like	 floseal,	 been	 shown	 to	 cause	 a	 granulomatous	
foreign	 body	 reaction(231).	 	 There	 is	 a	 variable	 immune	 response	 in	 patients	 on	 whom	
Surgiflow	has	been	used.	The	baseline	safety	study	showed	anti-porcine	collagen	antibodies	
developed	 in	 6/206	 patients	 compared	 with	 a	 single	 patient	 who	 had	 these	 at	 the	
commencement	of	the	study(231).	The	risk	of	clinically	apparent	adverse	events	does	not,	
however,	 appear	 to	 differ	 between	 bovine	 and	 porcine	 origin	 thrombin	 as	 assessed	 in	 a	




Clinically	 apparent	 adverse	 effects	 have	 been	 reported	with	 the	 use	 of	 topical	 thrombin,	
specifically	 of	 bovine	 origin(233-235).	 Factor	 V	 antibodies	 may	 develop	 as	 a	 response	 to	
exposure.	These	inhibitors	block	the	normal	coagulation	function.	Approximately	126	cases	
have	 been	 reported	 worldwide,	 approximately	 2/3	 of	 which	 are	 post	 bovine-thrombin	
exposure.	 33%	 of	 these	 developed	 clinically	 apparent	 bleeding	 problems(233).	 If	















deep	 vein	 thrombosis	 formation.	 Safaee	et	 al	 published	a	 single	 institution	 review	of	 467	
patients	 undergoing	 craniotomy	 for	 meningioma(237).	 2.6%	 of	 these	 patients	 suffered	 a	
thromboembolic	 event	 (DVT/PE).	 In	 univariate	 analysis,	 the	 authors	 found	 that	 higher	
tumour	grade	and	higher	body	mass	index	(BMI)	were	positively	associated	with	the	chance	
of	developing	thromboembolic	complications.	In	multivariate	analysis,	they	found	that	BMI	




community,	 but	 accepted	 practice	 is	 to	 commence	 DVT	 prophylaxis	 either	 immediately	
post-operatively	 or	within	 24	 hours	 after	 a	 post-operative	 CT	 or	MRI	 scan	 to	 ensure	 that	
there	is	no	haematoma	formation(238,	239).		
There	 are	 also	 isolated	 case	 reports	 of	 venous	 air	 embolism	 associated	 with	 the	 use	 of	
Floseal(240).	This	complication	occurs	when	operating	with	the	head	at	a	higher	level	than	
the	heart.	 If	a	venous	sinus	is	opened,	air	(and	potentially	Floseal)	may	be	sucked	into	the	






It	 does	 not,	 however,	 appear	 to	 be	 a	 common	 event	 and	 is	 a	 potential	 risk	 at	 any	 point	






There	 are	 several	 commercially	 available	 fibrin-based	 sealants(242).	 These	 are	 generally	
composed	 of	 varying	 ratios	 of	 human	 plasma-derived	 thrombin	 and	 fibrinogen.	 Their	










an	 adjunct	 for	 haemostasis.	 It	 consists	 of	 55-85	 mg/ml	 fibrinogen	 and	 800-1200	 IU/ml	
human	 thrombin	 in	 frozen	 solution.	 It	 is	 provided	 in	 separate	 vials	which	 are	mixed	 in	 a	
sterile	applicator.	They	are	stored	in	a	refrigerator	and	may	be	mixed	and	ready	to	apply	in	
<1	minute.	It	is	dripped	or	sprayed	onto	the	wound.	This	may	be	assisted	with	an	air	pump	
as	 the	 provided	 cannula	 has	 a	 tri-lumen	 to	 ensure	 that	 the	 products	mix	 at	 the	 tip.	 The	
manufacturer	 advises	 caution	when	using	 the	 air	 pump	 to	 avoid	 the	occurrence	of	 an	 air	
embolism(254).	It	is	derived	from	human	plasma	so	the	theoretical	risk	of	infectious	disease	









This	 did	 not	 affect	 the	 haemostatic	 effect	 of	 the	 fibrin/thrombin	 combination	 because	
plasminogen	 is	 also	 removed	 from	 the	 fibrinogen	 component	 by	 chromatographic	
techniques	 and,	 therefore,	 tranexamic	 acid	 is	 not	 required	 as	 a	 stabilizer(256).	 Fibrin	
sealants	 are	 broken	 down	 and	 metabolised	 by	 endogenous	 fibrinolytic	 activity.	 Healing	






Tisseal[Baxter]	 is	 a	 combination	 of	 human	 thrombin,	 human	 fibrinogen	 and	 a	 synthetic	
fibrinolysis	inhibitor	–	aprotinin	–	to	prevent	premature	degradation	of	the	clot(257,	258).	It	
can	 be	 used	 directly	 on	 the	 brain,	 dura	 and	 spinal	 cord	 and	 it	 has	 been	 described	 as	 an	
adjunct	to	cavernous	sinus	surgery	 in	which	 it	 is	 injected	 into	the	cavernous	sinus	prior	to	
tumour	 dissection	 to	 minimise	 peri-capsular	 bleeding(243,	 259).	 It	 will	 adhere	 to	 a	 wet	
surface	however	the	flow	rates	of	torrential	arterial	bleeds	mean	that	it	is	unable	to	provide	
adequate	haemostasis	unless	it	can	be	held	in	situ	as	part	of	a	patch(260).	There	is	evidence	
to	 show	 that	 it	 reduces	 time	 to	 haemostasis	 and	 blood	 loss	 in	 vascular	 anastomosis	
lines(260,	261).	A	randomized	non-blinded	trial	of	17	patients	was	performed	to	determine	
whether	 topical	 fibrin	 sealant	 reduced	 anastomosis	 suture	 line	 bleeding	 during	 carotid	
endarterectomy	with	polytetrafluoroethylene	 (PTFE)	patch	 closure.	 Time	 taken	 to	achieve	
haemostasis	 at	 the	 suture	 line	and	 intraoperative	blood	 loss	were	measured.	The	median	
time	to	achieve	haemostasis	was	5.5	min	(range	4-31	rain)	 in	the	treatment	group	and	19	
min	(range	10--47	min)	in	the	control	group	(P<0.005).	Operative	blood	loss	was	lower	in	the	
treatment	 group	 (median	 420mi,	 range	 300-500mi)	 than	 in	 the	 control	 group	 (median	
550ml,	range	350-1200ml)	however	this	was	not	statistically	significant(261).	These	findings	












243,	 247,	 248).	 This	 crosslink	 stability	 has	 been	 shown	 in	 a	 number	 of	 studies	 where	
Evicel[Ethicon]	was	compared	with	Tisseal[Baxter].	The	resultant	Evicel	fibrin	clots	had	more	
tensile	 strength	 than	 Tisseal	 on	 skin	 adhesive	 tests	 (0.25N	 vs.	 0.08-0.11N	 p£0.006)(263)	
however	 other	 studies	 have	 shown	 less	 clear	 results(241,	 242).	 This	 difference	 in	 clot	
stability	may	be	due	to	the	fact	that	the	fibrin	component	of	Evicel	has	detectable	levels	of	






In	 a	 vascular	 surgical	 prospective	 randomised	 controlled	 trial,	 Evicel	 (75	 patients)	 was	
compared	with	manual	compression	only	 (72	patients)	 in	patients	undergoing	end	 to	side	
femoral	 or	 upper	 extremity	 arterial	 anastomoses(245).	 These	 grafts	 were	
polytetrafluoroethylene-based.	 Evicel	 was	 significantly	 more	 effective	 at	 achieving	
haemostasis	 than	 manual	 compression	 alone	 at	 the	 4-minute	 mark	 (85%	 vs	 35%).	 The	
incidence	of	treatment	failure	was	also	lower	in	the	Evicel	group(245).	Graft	thrombosis	or	
occlusion	occurred	in	8%	of	the	Evicel	group	compared	with	1%	in	the	manual	compression	
group	 in	 the	 early	 post-operative	 stage	 out	 to	 12	 days.	 When	 reassessed	 at	 5	 weeks	
postoperatively,	 an	 additional	 3%	 of	 Evicel	 group	 patients	 had	 suffered	 a	 graft	 occlusion	
compared	with	7%	of	 the	manual	 compression	group.	9%	of	 the	Evicel	 group	 (7	patients)	











This	 positive	 haemostatic	 effect	 was	 also	 shown	 in	 a	 study	 comparing	 Evicel	 (when	
formulated	 as	 Quixil)	 to	 Kaltostat	 (a	 calcium	 alginate	 dressing)	 in	 carotid	
endarterectomies(265).	 Primary	 outcomes	 were	 median	 time	 to	 haemostasis	 and	 mean	
blood	 loss.	Quixil	was	placed	onto	 the	suture	 line.	The	 interim	analysis	was	so	compelling	
after	20	patients	 in	 favour	of	Quixil	 that	 further	 recruitment	was	 ceased.	Median	 time	 to	

















theoretical	 risk	 of	 transmission	 of	 blood-borne	 diseases	 with	 fibrin	 sealants	 of	 human	
derivation.	This	risk	is	minimised	by	screening	of	donors,	inactivation	of	viruses	and	testing	





























to	 the	 site	 of	 bleeding	 and	 compression	 applied	 for	 ten	 minutes(282).	 This	 is	 a	 large	
bandage	 and	 used	 primarily	 to	 staunch	 haemorrhage	 from	 bullet	 and	 blast	 injuries	 in	 an	
‘immediate	 response’	 setting	 to	allow	 the	patient	 time	 to	 reach	definitive	 surgical	 care.	 It	





Syvek	 is	 a	 soft,	white,	 sterile,	 non-woven	pad	of	poly-N-acetyl	 glucosamine	 fibres	derived	
from	 algae.	 It	 is	 attached	 to	 a	 foam	 backing	 and	 is	 marketed	 commercially	 in	 both	 the	
United	States	and	Australia	as	a	sealing	dressing	for	the	femoral	artery	post	angioplasty(283,	
284).	The	glucosamine	 fibres	 induce	vasoconstriction	mediated	via	endothelin	 release	and	
activate	plasma	clotting	proteins	and	platelets.	Studies	 in	cardiology	patients	demonstrate	
its	 efficacy	 with	 only	 a	 1.4-2%	 failure	 rate	 in	 >600	 patients(285).	 Syvek	 has	 regulatory	
approval	 for	 use	 in	 the	 United	 States	 and	 Australia	 in	 an	 external	 fashion	 only.	 Animal	
studies	on	 rat	 aorta	have	demonstrated	 that	 Syvek	 causes	arterial	 vasoconstriction	 in	 the	












cautery)	 is	 ineffective	 or	 impractical(287).	 The	 Patch	 consists	 of	 human	 fibrinogen	 and	
human	 thrombin	 embedded	 in	 a	 flexible	 composite	 patch	 component.	 The	 patch	 is	
absorbable.	It	contains	8.6	mg	per	square	cm	of	human	fibrinogen	and	37.5	Units	per	square	
cm	 of	 human	 thrombin.	 Upon	 contact	 with	 a	 bleeding	 wound	 surface,	 the	 biological	
components	 embedded	 in	 the	 patch	 component	 are	 hydrated,	 and	 the	 subsequent	
fibrinogen-thrombin	reaction	initiates	the	last	step	in	the	conversion	of	fibrinogen	into	fibrin	
monomers	 that	 further	polymerize	 to	 form	a	 fibrin	clot(287,	288).	Hemostasis	 is	achieved	
when	the	formed	fibrin	clot	integrates	with	the	patch	component	and	adheres	to	the	wound	
surface	 thus	 providing	 a	 physical	 barrier	 to	 bleeding.	 Evarrest	 has	 been	 shown	 to	 have	 a	
statistically	 significant	difference	compared	 to	usual	 standard	of	 care	 in	 the	proportion	of	
subjects	achieving	haemostasis	at	4	minutes	after	 identification	of	the	target	bleeding	site	













2.7	 Units	 (2.0	 U)	 per	 cm2(291).	 It	 is	 thought	 that	 it	 works	 in	 a	 similar	 fashion	 to	 other	
thrombin/fibrin	patches	by	activation	of	 fibrinogen	 into	 fibrin	monomers	with	subsequent	
polymerization	into	a	clot	and	platelet	activation.	The	fibrin	polymers	and	platelet	activation	
lead	 to	 subsequent	 activation	 of	 the	 coagulation	 cascade	 with	 further	 adherence	 to	 the	
wound	 surface	 via	 further	 thrombin	mediated	 fibrin	 polymerization	 and	 conglutination	of	
the	patch’s	 collagen	matrix	and	 the	wound	 surface,	 forming	a	 tight	 seal(293).	 The	human	





Tachosil	 is	 indicated	 for	 use	 in	 cardiac	 and	 hepatic	 surgery	 as	 an	 adjunct	 to	 haemostasis	
where	it	 is	placed	as	a	sheet	upon	the	bleeding	surface(291).	The	literature	is	replete	with	
case	reports	and	small	series	of	novel	use.	Several	cardiac	case	studies	report	its	use	to	seal	
ventricular	bleeding	post	 infarction	and	 rupture	 and	at	 least	one	 case	of	 its	 use	 to	 seal	 a	
high	 pressure	 ruptured	 coronary	 artery(296-299).	 It	 has	 also	 been	 trialed	 to	 prevent	 the	
development	 of	 pericardial	 adhesions	 post	 cardiac	 surgery(300,	 301),	 been	 used	 in	 swine	









a	 haemostat	 and	 as	 a	 dural	 sealant	 with	 a	 mean	 follow	 up	 of	 4	 months.	 Indications	 for	
neurosurgery	 varied	 but	 included	 tumour	 surgery	 (53%),	 cerebral	 aneurysm	 (31%),	
Arteriovenous	malformation	(4%)	and	cavernoma	(4%).	The	remainder	were	spinal	tumours	
and	chronic	subdural	haematoma(293).	The	authors	describe	its	use	in	a	number	of	settings	
from	 stopping	 small	 arteriole	 bleeding	 to	 reinforcing	 suture	 lines	 as	 a	 dural	 sealant.	 The	
most	applicable	 from	a	haemostatic	perspective	was	 its	use	to	repair	 the	superior	sagittal	
sinus	 in	 vertex	 and	 parafalcine	 meningioma	 surgery.	 Conventional	 teaching	 is	 that	 the	
anterior	1/3rd	of	the	sinus	may	be	resected	without	neurological	deficit	occurring	but	that	
resecting	the	posterior	2/3rds	will	 result	 in	venous	 infarction	of	the	cortex	and	potentially	
death(28,	115,	311).	 In	 this	 series,	 the	authors	describe	 laying	 the	 tachosil	 in	 strips	cut	 to	









as	 it	 occasionally	 pulled	 the	 patch	 off	 the	 bleeding	 point	 with	 further	 haemorrhage.	 To	








layers	 of	 aortic	 dissection	 before	 a	 new	 aortic	 ring	 was	 sutured	 in	 place(312).	 This	 was	
designed	 to	 ensure	 adhesion	 between	 the	 dissected	 layers	 and	 prevention	 of	 further	
propagation	of	the	dissection	distally.	There	was	no	evidence	of	recanalization	of	the	false	
lumen	 once	 it	 had	 been	 treated	 with	 tachosil	 insertion	 and	 no	 evidence	 of	 neurological	
impairment	in	the	10	survivors	of	the	procedure	and	perioperative	period.	There	were	two	













not	 appear	 to	 carry	 an	 increased	 risk	 of	 systemic	 or	 localized	 thromboembolic	
complications(234).	 It	 is	 important	 to	 acknowledge	 that	 given	 the	 proposed	 trial	 of	 this	















form	 a	 physical	 barrier	 to	 blood	 or	 cerebrospinal	 fluid.	 These	 include	 cyanoacrylate	
absorbable	 sealant	 that	 polymerises	 on	 contact	 with	 tissues	 and	 glutaraldehyde	 bovine	
albumin	 glue(315-317).	 Research	 has	 also	 been	 performed	 on	 systemic	 agents	 that	 may	
influence	 the	 coagulation	 pathways.	 Tranexamic	 acid	 to	 prevent	 fibrinolysis	 and	
recombinant	factor	VII	have	been	trialed	however	their	use	is	generally	more	appropriate	in	





















reports	 of	 foreign	 bodies	 becoming	 lodged	 in	 the	 cerebral	 vasculature,	 sometimes	 quite	
delayed	 post	 the	 initial	 event(320,	 321).	 The	 most	 common	 of	 these	 are	 high	 velocity	
projectiles	such	as	shotgun	pellets(165,	322-324).	These	have	caused	a	number	of	vascular	
pathologies,	 the	 most	 common	 being	 strokes	 and	 fistulae(325).	 There	 are	 however,	 also	
several	 reports	of	 iatrogenic	 thromboembolism	of	hydrophilic	polymer	coating	of	vascular	

























more	 clearly	 defined,	 synthetic	 agents	 are	 better	 able	 to	 be	 engineered	 to	 activate	 or	
augment	 intrinsic	 mechanisms(334).	 The	 majority	 of	 them	 are	 derived	 from	 human	 or	
animal	 (generally	 bovine	 or	 ovine)	 sources	 and	 consist	 of	 purified	 or	 refined	 forms	 of	
















able	 to	 be	 readily	 applied	 within	 a	 matter	 of	 seconds	 from	 its	 storage	 state	 without	
activating	substances	needing	to	be	added.	
	
Qin	 et	 al	 have	 demonstrated	 an	 elegant	 potential	 solution	 to	 this	 problem.	 They	 have	
covalently	 bonded	 thrombin-receptor-agonist-peptide-6	 (TRAP-6)	 to	 a	 poly-vinyl	 alcohol	
(PVA)	 hydrogel(334).	 Once	 platelets	 become	 activated,	 they	 express	 GPIIbIIIa	 on	 their	




hydrogel,	 the	 clotting	 time	was	 reduced	by	 45%	when	 compared	 to	 physiological	 clotting	
time.	 It	 was	 also	 able	 to	 cause	 platelet	 activation	 as	 measured	 by	 multiplate	 analysis	









Hydrogels	 are	networks	of	polymer	 chains	 that	 are	hydrophilic	 and	high	 in	water	 content	
(usually	>90%).	They	are	very	absorbent	and	 flexible	due	to	 this	water	content.	Hydrogels	
form	a	net-like	 structure	with	multiple	voids	which	 increase	 their	water	carrying	capacity.	
An	 in-situ	 hydrogel	 is	 one	which	 is	 liquid	 at	 room	 temperature	 but	 becomes	 a	 gel	 under	
specific	 conditions,	 whether	 this	 is	 due	 to	 ionic-cross	 linking,	 temperature,	 or	 pH(339).	
These	 hydrogels	may	 act	 as	 a	 base	material	 whose	 properties	 can	 be	manipulated	 for	 a	
desired	 effect.	Gong	et	 al,	 for	 example,	 developed	 a	hydrogel	 polymer	with	 antimicrobial	
properties(340).	This	 is	due	 to	 the	addition	of	a	 long	 lipophilic	alkyl	 chain	 that	penetrates	
bacterial	 membranes	 and	 causes	 autolysis	 and	 cell	 death(340).	 Recent	 research	 has	
focussed	 on	 the	 use	 of	 hydrogels	 as	 dressings	 promoting	wound	 healing,	 as	 scaffolds	 for	
drug	 delivery	 that	 are	 able	 to	 release	 their	 therapeutic	 drug	 load	 only	 under	 certain	
physiological	conditions,	and	as	contact	lense	components(339,	341-343).		
	
Lih	et	al	 combined	chitosan	with	poly-ethylene-glycol	which	allows	 this	 to	 form	an	 in	 situ	
hydrogel(316).	They	then	evaluated	the	adhesive	strength	and	wound	healing	ability	of	this	
hydrogel	 in	 vitro	 and	 in	 vivo	 in	 a	 mouse	 model	 of	 liver	 haemorrhage.	 With	 regard	 to	
haemostasis	in	vivo,	the	hydrogel	reduced	blood	loss	by	2/3rds	(154mg	vs.	59mg)(316).	The	
in	 situ	hydrogel	gelated	within	5	 seconds	and	demonstrated	an	adhesive	 strength	of	3-20	
times	that	of	a	fibrin	glue	used	as	a	comparator(316).	This	adhesiveness	was	thought	to	be	
due	 to	 the	 interaction	of	positively	 charged	amino	groups	of	 the	 chitosan	with	negatively	








Original	 formulations	 of	 chitosan-based	 hydrogels	 suffered	 from	 the	 inability	 to	 gelate	
quickly	 enough	 for	 use	 as	 a	 haemostatic	 agent.	 Nie	 et	 al	 have	 developed	 a	 chitosan/e-
polylysine	hydrogel	with	a	fast	crosslinking	rate	by	the	addition	of	maleimide	group	that	acts	
as	 a	 peptide	 crosslink.	 The	 gelation	 time	was	 reduced	 from	60	minutes	 to	 15seconds	 +/-
3sec(344).		
	
Behrens	 et	 al	 manufactured	 a	 N-(3-aminopropyl)methacrylamide	 hydrochloride	 (APM)	
hydrogel	that	was	dehydrated	and	formed	into	spheres(345).	These	were	then	mixed	with	
ovine	 blood.	 Their	 baseline	 size	 ranged	 from	 500-1000	 micrometers.	 Once	 mixed	 with	
blood,	they	increased	in	size	to	1400-2900	micrometers.	This	equated	to	a	1600%	increase	
in	mass	and	a	1687%	increase	in	volume.	These	particles	were	used	on	a	mouse	liver	and	tail	





















state”	 which	 formed	 a	 mesh	 with	 100	 nanometre	 pores(346).	 Blood	 loss	 in	 both	
experimental	 injuries	 was	 significantly	 reduced	 (0.16g	 vs.	 0.72g).	 A	 small	 amount	 of	 this	
nano-peptide	hydrogel	was	placed	within	the	paravertebral	musculature	of	rabbit.	This	was	




















These	 experiments	 go	 some	 way	 towards	 validating	 the	 concept	 of	 engineering	
‘haemostasis	activators’	that	can	immediately	be	used	to	control	bleeding.	It	remains	to	be	
determined	the	effect	that	these	substances	will	have	on	tissues	and	whether	they	provide	
long	 term	 control.	 Further,	 animal	 studies	 will	 be	 required	 to	 not	 only	 examine	 their	






and	algal	sources.	 In	 its	natural	form,	 it	 is	a	major	component	of	crustacean	exoskeletons,	
squid	 pens,	 the	 wings	 of	 insects,	 marine	 algae,	 or	 fungal	mycelial	 mats(279,	 348-350).	 It	
consists	 of	 polymers	 in	 a	 crystalline	 form.	 These	 polymers	 are	 arranged	 in	 either	 parallel	
lines	(where	they	may	be	termed	b-chitin)	or	antiparallel	lines	(where	they	may	be	termed	
a-chitin)	which	are	held	 together	by	a	 combination	of	 van	der	Waal	 forces	and	hydrogen	
bonds.	 They	 are	 able	 to	 be	 formed,	 via	 temperature	 variation	 and	 various	 solvents,	 into	
nano-fibres	measuring	 60-100	micrometers	 in	 length	 and	 20-80	 nanometres	 in	 diameter.	
The	 marine	 form,	 derived	 from	 microalgae,	 forms	 a	 beta-pleated	 sheet(350-353).	 The	








Chitin	 is	 a	 heterogeneous	 mix	 of	 polymers	 with	 10-20%	 N-acetyl	 residues	 and	 80-90%	
glucosamine	residues(356).	This	heterogeneity	poses	a	problem	 in	utilising	the	pGlcNAc	 in	
medical	settings	where	standardisation	and	predictability	of	action	is	key.	This	problem	can	
be	 mitigated	 somewhat	 by	 combining	 chitin	 with	 alkaline	 substances	 such	 as	 sodium	




pGlcNAc	has	also	been	produced	 from	microalgae	 sources.	These	are	unique	because	 the	
polymer	fibres	are	bound	to	each	other	by	interchain	hydrogen	bonds	in	parallel	structure.	
These	 fibres	 have	 a	 diameter	 of	 2-4	 nanometres	 and	 are	 composed	 of	 approximately	 80	
polymers	per	 fibre.	They	are	able	 to	be	dissociated	 from	their	polymer	 form	by	hydrogen	











parallel	 fibres	 derived	 from	microalgae	 is	more	 effective	 in	 tests	 of	 haemostasis	 than	 the	
alpha-chitin	 form	of	pGlcNAc,	which	has	antiparallel	 fibres(365).	Deacetylation	of	chitin	 to	




demonstrated	 that	 contact	 with	 beta	 pGlcNAc	 caused	 total	 and	 irreversible	 activation	 of	
platelets.	P-selectin	was	expressed	on	 the	platelet	 surface	and	 there	was	a	morphological	
shift	 in	 the	 platelets	with	 pseudopodia	 demonstrated(366).	 The	 authors	 propose	 a	 three-
step	activation	mechanism(366)	




clot.	 This	 clot	 is	 further	 stabilised	 by	 the	 tendency	 for	 platelets	 to	 aggregate	 on	
pGlcNAc	matrices	 and	 generate	 vasospastic	 substances	 such	 as	 thromboxane	 and	
serotonin	
3. Clot	 retraction	 via	 platelet	 mediators	 and	 local	 vasospasm	 accelerates	 wound	
healing		
	
Valeri	 and	 colleagues	 used	 thromboelastography	 to	 demonstrate	 platelet	 activation.	 A	
mixture	of	platelet	poor	plasma,	platelet	rich	plasma	or	platelet	rich	plasma	with	red	cells	to	







Fischer	 et	 al	 performed	a	 series	 of	 experiments	 to	determine	 the	mechanical	 events	 that	
lead	 to	 platelet	 activation	 when	 exposed	 to	 algae-derived	 pGlcNAc.	 They	 identified	 the	
plasma	 and	 surface	 proteins	 involved,	 the	 effect	 of	 integrin	 inhibitors	 and	 intrinsic	
coagulation	 pathway	 turnover	 on	 fibrin	 polymerisation	 and	 the	 intracellular	 signalling	
processes	that	activate	platelets.	Their	conclusion	was	that	the	effect	was	multifactorial	but	
they	did	determine	 that	GP1b,	a	platelet	protein	 that	ordinarily	binds	 to	von	Willebrand’s	
factor,	binds	strongly	 to	 the	pGlcNAc	 fibres	 to	prevent	platelet	shearing	and	allow	further	
binding	to	fibrin(194).		
	
Follow	 up	 work	 by	 the	 same	 group	 using	 thromboelastography	 demonstrated	 that	 beta	
pGlcNAc	 (marine	 algae	 source)	 accelerated	 fibrin	 polymerisation	 to	 the	 extent	 that	 it	
negated	 the	 effect	 of	 GPIIbIIIa	 inhibition.	 Blood	 treated	 with	 eptifibatide	 (a	 GPIIbIIIa	
inhibitor)	 inhibited	 platelet	 aggregation.	 When	 beta	 pGlcNAc	 fibres	 were	 added,	 this	
inhibition	 was	 reversed.	 The	 kinetics	 of	 blood	 treated	 with	 aspirin	 or	 clopidogrel	 where	
unchanged	compared	with	normal	blood	when	mixed	with	pGlcNAc	fibres(354).	The	authors	

















































Jegatheeswaran	and	colleagues	performed	 in	vivo	experiments	 to	determine	 the	effect	of	
pGlcNAc-	derived	chitosan	on	haemostasis	in	an	ovine	hepatic	injury(367).	They	performed	






chitosan	 sponges	 to	 fibrin/thrombin	 patches	 (TachoComb)(368).	 They	 demonstrated	 no	













Chitosan	 is	 thought	 to	 increase	 granulation	 around	wound	 sites.	 As	 it	 is	 broken	 down,	 it	







it	 does	 not	 result	 in	 allergic	 reactions	 in	 those	 patients	 susceptible	 to	 this.	 The	 true	
incidence	of	shellfish	allergy	is	unknown	but	population	studies	have	placed	it	somewhere	in	
the	 range	 of	 0.5%-3.8%(371).	 Reactions	 vary	 from	 the	 potentially	 life-threatening	
anaphylaxis	to	mild	skin	reactions.	There	are	over	50,000	different	species	of	shellfish	and	
over	 100,000	 species	 of	molluscs	 described(371).	 The	 precise	 allergen	 is	 often	 difficult	 to	
determine	 and	 further	 testing	 is	 rarely	 performed.	 Once	 a	 shellfish	 allergy	 has	 been	
diagnosed,	the	advice	is	often	simply	to	avoid	the	entire	shellfish	family(371-373).	There	are	
several	individual	allergens	that	have	been	identified	including	Tropomyosin	(TM),	arginine	






fungi	 is	 part	 of	 a	 complex	 structure	 and	 not	 found	 in	 a	 purified	 form.	 It	 is	 generally	
covalently	 linked	 to	 proteins	 and,	 in	 fungi,	 linked	 to	 glucans.	 This	 is	 very	 different	 to	 the	
regulated	and	highly	associated	structure	of	purified	chitin	used	in	vitro(362).	
	
Chitin	 is	 known	 to	 be	 involved	 in	 host	 tissue	 responses	 to	 allergy(374,	 375).	Workers	 in	
shellfish	processing	plants	are	known	to	have	higher	levels	of	allergy	and	‘shellfish	asthma’	
is	a	recognised	disease	by	the	centre	for	disease	control	with	a	prevalence	of	2-36%(376).	
These	workers	are	also	known	to	have	a	higher	 level	of	allergy	to	mites	and	 insects,	 likely	
reflecting	 the	 homogeneity	 of	 the	 protein	 structures	 in	 their	 shells(376).	 There	 is	 some	
evidence	that	the	chitin	in	fungal	cell	walls	induces	a	T-helper	cell	type	2	(Th2)	response	and	







Chitin,	 when	 introduced	 into	 the	 lungs	 of	 mice,	 causes	 an	 allergic	 response	 with	 both	
basophil	and	eosinophil	migration	within	6	hours	and	upregulation	of	the	gene	coding	for	an	
enzyme	 that	 breaks	 down	 chitin	 (chitinase)(374).	 There	 is,	 however,	 some	 conflicting	
evidence	that	chitin	itself	may	actually	down-regulate	adaptive	type	2	allergic	responses	to	
subsequent	 allergens	 and	 be	 beneficial	 in	 humans(378).	 Chitin	 fibres	 introduced	 into	 the	





difference	 in	 the	 literature	 is	 thus	 far	 non-significant(378).	 	 In	 studies	 of	 quantitative	
measures	 of	 circulating	 inflammatory	 cells,	 the	 presence	 of	 chitin	 in	 the	 spleen	 reduces	
expression	of	allergen-associated	interleukins	IL-4,	IL-5	and	IL-10(362,	379,	380).		
	








as	 "crustacean	 derivatives",	 because	 the	 isolation	 procedures	 have	 removed	proteins,	 fats	
and	 other	 contaminants	 to	 such	 an	 extent	 as	 to	 allow	 them	 to	 be	 classified	 as	 chemicals	
















the	 ability	 to	 administer	 a	 substance	 that	 either	 provides	 a	 scaffold	 for	 ordered	 cellular	
regeneration	or	delivers	growth	factors	that	stimulate	such	recovery	is	attractive,	especially	






et	 all	 have	 pointed	 out,	 “versatile	 building	 blocks	 for	 fabricating	 supramolecular	
architectures”(365).	 The	 development	 of	 these	 has	 come	 about	 through	 increased	
understanding	of	 the	protein	 chains	 found	 in	naturally	occurring	 substances.	Peptide	 self-
assembly	 is	 a	 complex	 interaction	 of	 forces	 including	 hydrogen	 bonding,	 ionic	 forces,	




uses	 for	 these	peptides	 include	drug	delivery,	 scaffold	 sheaths	 for	 neural	 redevelopment,	
and,	importantly,	haemostasis.		
	

















as	 strands.	 These	 are	 connected	 laterally	 by	 hydrogen	 bonds	 (generally	 2-3	 bonds	 per	
strand).	 Together,	 these	 form	a	 twisted	 sheet	 of	 protein	 chains.	 These	 can	be	 synthesised	























a	 self-assembling	 peptide	 to	 provide	 a	 scaffold	 or	 bridge	 for	 axonal	 regeneration	 in	 optic	
nerve	 reconnection(383).	 A	 peptide	 chain	 self-assembled	 into	 a	 b-pleated	 sheet	 named	
RADA16	has	been	used	 to	deliver	epidermal	 growth	 factor	 to	 increase	 the	 rate	of	wound	
healing	 and	 insulin-like	 growth	 factor,	 platelet-derived	 growth	 factor	 and	 stromal	 cell-
derived	 growth	 factor-1	 to	 post-infarction	 myocardium(365).	 These	 hydrogels	 allow	 the	








field	 of	 cancer	 medicine	 that	 nanostructures	 could	 change	 the	 extracellular	 matrix	 that	
facilitates	cancer	metastasis	and	ensure	malignancy	remains	localised(393).	 	When	applied	
to	 drug	 delivery,	 nanobiotechnology	 may	 solve	 the	 problem	 of	 permeation	 through	 cell	
membranes.	 At	 less	 than	 10nm,	 particles	 within	 the	 human	 body	 can	 be	 thought	 of	 as	





‘Nano-haemostat’	 refers	 to	 an	 amino	acid	 chain	 forming	a	 self-assembling	peptide	 that	 is	
used	 as	 a	 scaffold	 for	 haemostasis,	 potentially	 trapping	 endogenous	 coagulation	 factors	
around	the	site	of	bleeding.		There	are	multiple	different	types	and	formulations	described	
but	 they	 common	 features	 are	 that	 they	 comprise	 a	 dissolvable	 L-amino	 acid	 chain	 that	
does	not	interfere	with	cellular	pathways	or	promote	or	inhibit	signaling	and	that	is	broken	
down	 via	 the	 body’s	 natural	 peptidases	 and	 enzymes	 to	 constituent	 amino	 acids	 after	 its	
primary	role	has	been	performed(389).	There	are	a	number	of	studies	demonstrating	almost	
immediate	 haemostasis	 in	 small	 animal	 models	 without	 activation	 of	 the	 coagulation	
cascade.	 This	 has	 been	 demonstrated	 on	 mammalian	 brain,	 spinal	 cord,	 liver,	 kidney,	













use(389).	When	 applied	 specifically	 to	 the	 problem	 of	 bleeding	 in	 endoscopic	 surgery,	 it	





(including	muscle	 patches(117-121),	 Floseal,	 tisseal,	 thrombin	with	 gelatin(223,	 398),	 and	









Nano-haemostat	 appears	 to	 form	 a	 scaffold	 around	 bleeding	 vessels	 independent	 of	 any	
coagulation	or	platelet	pathway(394,	399,	400).	Previous	research	in	a	rat	model	has	shown	
that	 not	 only	 does	 it	 stop	 bleeding,	 but	 that	 this	 scaffold	 is	 then	 broken	 down	 into	
constitute	 amino	 acids(384).	 It	 also	 has	 the	 advantage	of	 being	 a	 liquid	 and	 is	 thus	more	





Nano-haemostat	 is	 applied	 in	 liquid	 form	 when	 first	 mixed	 before	 gelating	 around	 the	
bleeding	 structure.	Whilst	 it	has	been	proven	 to	be	 successful	 in	a	 small	 animal	model	of	
vessel	 injury,	this	may	not	hold	true	 in	 larger	animal/human	models	where	pressures	may	
be	many	 times	 that	 of	 smaller	 animals(332,	 390,	 398,	 401).	 	 This	 pressure	may	wash	 the	





Safety	 studies	will	 also	be	needed	 if	nano-haemostat	 is	 to	be	used	 in	 the	central	nervous	
system.	The	build-up	of	abnormal	proteins	within	the	central	nervous	system	is	pathological	
and	 the	 basis	 for	 the	 development	 of	 diseases	 such	 as	 dementias	 and	 prion	 diseases.	 It	





































Self-assembly	of	d-EAK16	was	timed	 in	a	pure	water	solution	and	 in	a	 living	animal	model	
(rabbit	 liver).	 It	 took	~16	hours	 for	d-EAK16	 to	 self-assemble	 in	water	but	~20	 seconds	 to	
self-	assemble	and	control	haemorrhage	 in	bleeding(400).	The	authors	conclude	that	 ions,	
proteins,	 enzymes	and	 “other	 factors”	 in	blood	work	 cooperatively	 to	 cause	haemostasis.	
Their	 rationale	 is	 that	 normal	 haemostasis	 occurs	 when	 there	 is	 a	 high	 concentration	 of	
clotting	factors	held	within	a	localised	area	whereas	the	same	gross	number	of	coagulation	
components	would	be	ineffective	if	spread	out	over	a	larger	area.	A	solution	of	d-EAK16	is	
thought	 to	 be	 triggered	 by	 Na+,	 Cu2+,	 K+,	Mg+,	 Ca+,	 Fe3+	 and	 Zn2+	 to	 form	 a	 stable	 β	
pleated	 sheet	 in	 which	 endogenous	 coagulation	 factors	 become	 trapped	 and	 undergo	
activation	in	the	usual	fashion.	This	β	pleated	sheet	however	is	not	the	final	form	the	nano-





were	 filled	 with	 RADA-16,	 bone	 wax	 or	 saline.	 Whilst	 the	 RADA-16	 and	 bone	 wax	 were	
comparable	 in	 terms	 of	 haemostatic	 efficacy,	 the	 RADA-16	 permitted	 significant	 new	
osteogenic	activity	as	opposed	to	the	bone	wax,	which	impaired	new	bone	formation.	The	












AC5	 is	 a	 proprietary,	 synthetic,	 nano-haemostat	 formulation(404).	 Currently	 in	 the	 initial	
phases	 of	 human	 trials,	 AC5	 addresses	 the	 potential	 for	 haemostasis	 in	 context	 of	
anticoagulation(390).	In	a	liver	punch	biopsy	model	in	rats(390),	AC5	achieved	haemostasis	
to	 the	 same	 pre-determined	 degree	 in	 heparinized	 and	 non-heparinized	 rats	 with	 a	 94%	
reduction	 in	 time	 to	haemostasis	 compared	 to	 saline	 controls(390).	A	 Full	 thickness	4mm	
punch	biopsy	to	ventral	liver	was	created	to	give	a	non-compressible	wound.	The	core	was	
then	 filled	with	 200	microliters	 of	 AC5-H	 or	 AC5-L	 or	 saline	 as	 control.	 Activated	 clotting	
time	(ACT)	and	partial	thromboplastin	time	(aPTT)	were	taken	from	animals.	Animals	were	







hydrogels.	 Sang	 et	 al	 performed	 a	 study	 in	 which	 they	 divided	 20	 rats	 in	 4	 groups	 –	 (1)	





ICH	was	 created	 via	 intrastriatal	 injection	 of	 collagenase.	 210	mins	 later,	 the	 haematoma	
was	 aspirated	 and	 20	 microliters	 of	 saline	 or	 RADA-16	 was	 injected	 into	 the	 ICH	 cavity.	
Differences	 in	 haematoma	 volume	 in	 aspiration	 vs	 saline	 vs	 RADA-16	 group	 were	 not	
significant.	Aspiration	with	injection	of	RADA-16	significantly	reduced	inflammatory	cells	in	
surrounding	 cortex	 on	 histological	 examination.	 There	 was	 a	 reduction	 in	 brain	 oedema,	
peri-haematoma	apoptosis	and	 inflammatory	 reaction	 in	 the	RADA-16	group.	The	authors	
concluded	 that	 self-assembling	 peptide	 attenuated	 brain	 injury,	 enhanced	 functional	
recovery	 and	 reduced	 cavity	 volume(384).	 This	 reduction	 in	 secondary	 brain	 injury	 is	
thought	 to	come	about	by	decreasing	 the	 leakage	of	 serum	proteins	 into	 the	surrounding	
parenchyma.	 Histology	 showed	 tight	 contact	 between	 self-assembling	 peptide	 and	 the	









of	 the	 nucleus,	 disappearance	 of	 the	 nucleolus	 and	 loss	 of	 nissl	 substance.	 There	 is	 an	
eosinophilic	appearance	to	the	cell(405).	Glial	cells	eventually	undergo	gliotic	change,	swell,	













Histological	 examination	 allows	 identification	 of	 the	 acute	 inflammatory	 response	 that	










that	 there	 is	 a	 variation	 in	 the	 time	 course	 of	 peak	 numbers	 of	 inflammatory	 cell.	 These	
studies	would	appear	to	indicate	that	in	order	to	determine	the	inflammatory	response	to	











prone	on	blocks	or	on	a	 Jackson	spinal	 table	after	 induction	of	general	anaesthesia.	After	




ligamentum	 flavum	 is	 then	 exposed	 and	 removed,	 generally	 with	 a	 kerrison	 punch.	 This	
exposes	the	thecal	sac.	From	here	the	operation	varies	depending	on	pathology.	On	closing,	
haemostasis	 is	 achieved	 in	 the	 field	 and	 the	 paraspinal	 muscles	 reapproximated	 with	
sutures.	The	lumbar	fascia	is	closed	and	the	extrafascial	space	obliterated	with	sutures.	The	
skin	and	subcutaneous	tissues	are	then	closed.	Patients	are	then	recovered	and,	generally,	




laminectomy	 vary	 widely	 but	 range	 from	 6-19%(412).	 This	 can	 be	 for	 a	 number	 of	




Posterior	 view	 of	 lumbar	 spine	 with	 spinous	 processes	 and	 lamina	 removed	 –	 section	



























operative	haematoma	 forms	over	 the	 thecal	 sac.	 This	 is	 then	 invaded	by	 fibroblasts	 from	
adjacent	muscle(420,	432,	433).	These	fibroblasts	encourage	the	formation	of	adhesions.	As	
patients	 mobilise,	 tension	 is	 placed	 upon	 nerve	 roots,	 facet	 joints	 and	 the	 surrounding	
tissues.	 This	 sensation	 is	 interpreted	 as	 pain(413).	 This	 adhesion	 work	 was	 first	
demonstrated	in	a	canine	model	by	LaRocca	and	McNab	in	1974(434).	They	demonstrated	
the	 progression	 of	 immediate	 post-operative	 haematoma	 through	 stages	 of	 fibroblast	
invasion	 and	 subsequent	 formation	 of	 a	 ‘laminectomy	 membrane’,	 which	 consisted	 of	 a	
fibrous	 scar	 covering	 the	 surface	of	 the	 thecal	 sac	 and	extending	 some	way	out	 over	 the	
nerve	 roots.	 These	 nerve	 roots,	 dorsal	 ganglion	 and	 facet	 joints	 all	 have	 sensory	
innervation(418,	435,	436).	Further	studies	have	 implicated	platelet	derived	growth	 factor	















dural	 opening(438-441).	 Some	 authors	 advocate	 using	 a	 pericranial	 graft	 at	 the	 time	 of	
operation	 whilst	 others	 use	 a	 synthetic	 graft	 to	 prevent	 periosteum	 and	 scalp	 flap	 from	
adhering	 to	 the	 brain	 and	 causing	 subsequent	 injury	 whilst	 raising	 the	 flap	 during	
cranioplasty(442).	There	is	evidence	that	there	is	a	higher	infection	rate	with	these	synthetic	





also	 potentially	 an	 increased	 risk	 of	 the	 development	 of	 early	 (<48hrs)	 post-operative	
haematoma	of	 up	 to	 18%(442).	 Interestingly,	 postulated	 reasons	 for	 this	 include	 that	 the	









Adhesions	 are	 generally	 measured	 using	 the	 ‘strip	 test’	 in	 which	 qualitative,	 blinded	
assessment	 is	 performed	 post	mortem	 by	measuring	 the	 resistance	 to	 separation	 of	 the	
tissue	 in	 question	 and	 its	 surrounding	 structures	 such	 as	 dura	 removal	 from	 paraspinal	
musculature	and	vertebra(433).		
	







There	 are	 a	 number	 of	 topical	 patches	 for	 dural	 repair	 currently	 commercially	 available.	
These	 include	thrombin-based,	cellulose	sheets,	 fibrin	gels,	hydrogels	and	combinations	of	
these(201,	 223,	 226,	 230,	 330,	 333,	 447,	 448).	 There	 are	 also	 gels	 that	 act	 as	 physical	






subsequently	 purified	 to	 minimise	 the	 risk	 of	 foreign	 body	 granulomatous	 reaction.	 It	 is	
provided	in	multiple	patch	sizes	and	used	as	a	dural	substitute	when	the	dura	is	unable	to	
be	closed	primarily.	It	is	postulated	to	work	as	a	dural	repair	matrix	providing	a	scaffold	for	
fibroblast	 infiltration	 and	 then	 being	 broken	 down	 at	 a	 rate	 comparable	 to	 endogenous	
tissue	 formation	 with	 decreased	 adhesion	 to	 pia	 and	 arachnoid(452,	 453).	 Studies	 have	
demonstrated	 mixed	 results.	 Whilst	 studies	 of	 its	 use	 on	 spinal	 patients	 post	 tumour	
resection	have	demonstrated	decreased	 incidence	of	 spinal	 adhesions	 and	CSF	 leaks(452-
455),	an	Ovine	study	demonstrated	increased	adhesion	to	brain	cortex	when	compared	with	


















porous	 matrix	 with	 10–100	 micron	 pores.	 This	 matrix	 is	 a	 scaffold	 for	 the	 ingrowth	 of	
















315,	 460).	 The	 hydrogel	 implant	 is	 absorbed	 in	 approximately	 4	 to	 8	 weeks	 and	 renally	







of	 action	 that	 work	 synergistically,	 the	 overall	 effect	 is	 to	 reduce	 inflammation.	 They	
prevent	 leukocyte	 migration	 to	 areas	 of	 inflammation	 or	 injury(462).	 	 Budesonide	 is	




















(1)	 saline	 control;	 (2)	 placement	 of	 the	 hydrogel	 mixture;	 (3)	 1mg/ml	
dexamethasone/hydrogel;	 (4)	 2mg/ml	 dexamethasone/hydrogel;	 (5)	 4mg/ml	
dexamethasone	 hydrogel.	 After	 4	 weeks,	 animals	 were	 sacrificed	 and	 the	 amount	 of	
adhesions	 quantified	 in	 2	ways.	 A	 single	 rat	 in	 each	 group	underwent	 re-exposure	 of	 the	
laminectomy	 site	 and	 the	 difficulty	 in	 re-exposure	 and	 inflammation	 in	 the	 surrounding	
tissues	was	scored.	The	remaining	rats	underwent	histological	examination	and	were	scored	
for	fibroblast	and	blood	vessel	density	and	extent	of	adhesions.	This	adhesion	quantification	










The	study	demonstrated	a	 significant	decrease	 in	adhesions	with	 the	hydrogel	barrier	but	
that	 there	 was	 not	 a	 reliably	 significant	 decrease	 in	 adhesions	 with	 the	 addition	 of	
dexamethasone,	nor	was	this	dose	dependant.	This	significant	reduction	 in	adhesions	was	
only	seen	in	the	2mg/ml	dexamethasone	concentration	cohort.	The	authors	attribute	this	to	


























iron	 in	 conditions	 such	 as	 thalassaemia	 where	 total	 iron	 is	 increased(469).	 Deferiprone	
complexed	to	iron	is	excreted	renally.	Iron	is	chelated	from	a	number	of	sources	within	the	
body,	 including	 ferritin,	 transferrin,	 hepatocellular	 iron	 and	 abnormal	 intra-erythrocyte	




ability	 to	 inhibit	 free-radical	 formation.	 Hydroxyl	 radicals	 are	 liberated	 by	 free	 iron	 in	
vivo(470,	471).	These	hydroxyl	 radicals	are	 toxic	 to	 tissues.	Experimental	 induction	of	 free	
radical	 damage	 to	 hepatocytes	 by	 exposure	 to	 hydrogen	 peroxide	 has	 been	 shown	 to	 be	










is	 modulated	 by	 iron	 loading	 in	 these	 monocytes(470,	 471).	 This	 iron	 is	 thought	 to	
upregulate	 chemokine	 receptors	 facilitating	 chemotactic	 protein-dependant	 trans-
endothelial	migration(470,	471).	 If	the	iron	was	chelated	and	the	monocytes	‘unloaded’	of	
their	 iron,	 this	 migration	 and	 adhesion	 was	 blocked.	 Iron	 may	 therefore	 play	 a	 role	 in	
inflammation	via	modulating	the	movement	of	pro-inflammatory	cells(471).		
	
Deferiprone	 has	 also	 been	 trialled	 as	 an	 antibacterial	 agent	 in	 staphylococcus	 biofilms.	
Staphylococcus	 requires	 iron	 and	 sequesters	 it	 from	 its	 host(476).	 Exposure	 of	
staphylococcus	biofilms	to	deferiprone	results	in	a	dose-dependent	reduction	of	biofilms	in	
vitro.	 This	 was	 enhanced	 by	 subsequent	 exposure	 to	 gallium	 protoporphyrin,	 a	 non-iron	
metalloporphyrin	which	acts	as	a	haem	analogue	and	is	taken	up	by	the	staphylococcus	in	












wound	 healing.	 Mohammadpour	 and	 colleagues	 showed	 improved	 cutaneous	 wound	
healing	in	rats	with	topical	application	of	deferiprone	at	3%,	6%,	and	9%(477).	The	authors	
also	used	DPPH	(2,2-diphenyl-1-picrylhydrazyl(478))	free	radical	assay,	an	antioxidant	assay	
that	 determines	 the	 ability	 of	 a	 substance	 to	 give	 hydrogen	 to	 a	 free	 radical	 and	 thus	










teamwork	 and	 decision	making	 are	 increasingly	 recognised	 as	 playing	 a	 crucial	 role(479).	
When	 all	 goes	 well	 with	 surgery,	 it	 is	 relatively	 easy	 to	 maintain	 open	 lines	 of	
communication	with	all	members	of	the	surgical	team	–	scrub	and	scout	nurses,	assistant,	
anaesthetist,	 orderlies	 and	 staff	 outside	 of	 theatre.	 It	 is	 when	 a	 potentially	 catastrophic	
event	occurs	 that	 coordinated	 teamwork	 is	 vital	 and	 clear	 and	 concise	 communication	 so	








surgery	 the	 high	 stakes	 of	 a	 bad	 outcome	 and	 has	 many	 parallels.	 Human	 performance	
assessment	 and	management	 in	 the	world	of	 aviation	has	much	 to	 teach	 surgeons	 about	
ways	 to	 train	 for	adverse	events.	Critics	of	 this	approach	argue	 that	 surgery	 is	 a	different	
beast	 to	aviation(483).	We	are,	after	all,	dealing	with	 the	human	body	with	all	 its	 frailties	









The	 Yerkes-Dodson	 performance	 curve	 was	 developed	 in	 an	 attempt	 to	 explain	 the	
relationship	 between	 arousal	 and	 performance.	 Their	 original	 work	 showed	 that	 mice	
performed	better	when	exposed	to	an	 intermediate-grade	aversive	stimulus	rather	 than	a	
high	one	when	performing	a	complex	task(489).	The	upward	slope	of	the	curve	represents	















the	 disturbed	 state	 itself…this	 bifurcation	 of	 meaning	 is	 arguably	 the	 most	 fundamental	
source	 of	 the	 confusion	 surrounding	 the	 stress	 concept(490).	 Traditional	 research	 has	
assumed	that	external	stimuli	generate	‘stress’	in	all	subjects	equally	and	researchers	then	
manipulate	 these	 variables	 (temperature,	 noise	 etc)	 and	 observe	 the	 effect	 on	 the	
individual.	This	does	not	allow	for	individual	differences	in	human	responses	and	emotions.	
This	 is	 termed	 the	 ‘stimulus-based’	 approach.	 An	 attempt	 to	 refine	 this	 has	 led	 to	 the	
‘response-based’	 approach,	 which	 defines	 stress	 as	 the	 pattern	 of	 responses	 that	 occur	
during	exposure	to	a	stimulus.	These	may	be	a	mix	of	physiological	and	psychological(490).	
This	 response-based	 approach	 has	 been	 extended	 further	 to	 what	 is	 termed	 the	










Physiological	 markers	 of	 stress	 range	 from	 easily	 measurable	 markers	 of	 sympathetic	
nervous	 system	 activation,	 such	 as	 hypertension	 and	 tachycardia,	 to	 serum	 levels	 of	
catecholamines,	such	as	noradrenaline	and	adrenaline,	and	hormones	such	as	cortisol(485,	
491).	Evidence	suggests	that	chronic	stress	may	be	reflected	by	a	high	cortisol	level	and	that	
this	 may	 have	 adverse	 long-term	 outcomes	 on	 immunity	 and	 cardiovascular	 health(492-
494).	 The	 half-life	 of	 cortisol	 and	 its	 secretion	 pathway	 preclude	 its	 use	 as	 a	 marker	 of	
immediate	 response	 to	 stress	 over	 seconds	 to	 minutes.	 Psychoneuroendocrinological	
studies	have	demonstrated	 the	utility	of	 salivary	alpha-amylase	as	a	marker	of	 immediate	
sympathetic	 nervous	 system	 activation	 with	 a	 reliable	 correlation	 with	 plasma	
catecholamines(492,	 495-501).	 This	 rises	 in	 response	 to	 acute	 stress(502,	 503).	 Salivary	
alpha-amylase	is	comprised	of	2	isoenzymes	with	a	molecular	weight	of	57000kDa(495).	It	is	
synthesised	primarily	 in	the	parotid	gland	and	hydrolyses	the	 linkages	of	starch	to	glucose	
and	 maltose(497).	 It	 initiates	 the	 digestion	 of	 starch	 in	 the	 mouth.	 Acinar	 cells	 are	
innervated	 by	 both	 the	 parasympathetic	 and	 sympathetic	 nervous	 system.	 The	
parasympathetic	 efferent	 pathway	 to	 the	 parotid	 gland	 is	 via	 the	 glossopharyngeal	 nerve	
and	 otic	 ganglion(53).	 The	 parasympathetic	 efferent	 pathway	 to	 the	 salivary	 and	
submandibular	 glands	 is	 via	 the	 facial	 nerve	 and	 the	 submandibular	 ganglion.	 The	






increases	 intracellular	 cAMP.	 Together	 these	 increase	 release	of	 salivary	 secretions	which	
are	stored	in	membrane	bound	secretory	granules(497).	Murine	models	have	demonstrated	
that	 sympathetic	 nervous	 system(SNS)	 stimulation	 to	 rat	 parotid	 results	 in	 a	 low	 flow	
rate/high	 protein	 salivary	 secretion.	 Parasympathetic	 nervous	 system	 (PSNS)	 stimulation	
results	in	the	opposite	effect(497).	Thus	mean	concentrations	of	salivary	alpha-amylase	are	




mental	 arithmetic(497,	 500).	 It	 is	 a	 generally	 accepted	 biomarker	 for	 acute	 stress	 in	 test	
subjects	in	the	psychoneuroendocrinological	 literature(504).	 	Salivary	alpha-amylase	would	
appear	 to	 hold	 promise	 as	 a	 biological	 marker.	 It	 reflects	 trends	 in	 sympathetic	 nervous	
system	 activation	 over	 the	 short	 term.	 It	 is	 easily	 collectable	with	 a	 salivary	 swab	 and	 is	






stress	 is	 probably	 that	 described	 by	McGrath	 in	 1976.	 Stress	 is	 “the	 interaction	 between	
three	 elements:	 perceived	 demand,	 perceived	 ability	 to	 cope,	 and	 the	 perception	 of	 the	
importance	of	being	able	to	cope	with	the	demand”(505).	Surgical	simulation	and	training	is	
therefore	 able	 to	 be	 focused	 on	 improving	 people’s	 perceived	 ability	 to	 cope	 through	







array	 of	 pathology	 in	 the	 human	 body	 that	 makes	 it	 impossible	 to	 state	 with	 absolute	




Simulation	 in	 surgery	 is	 a	 valuable	 tool.	 It	 has	 been	 incorporated	 into	 many	 training	
programs	 and	 varies	 widely	 from	 laparoscopic	 and	 animal	 training	models	 to	 videotaped	
sessions	with	 actors	 and	 other	members	 of	 the	 surgical	 team	 to	 develop	 communication	







As	has	previously	been	described,	there	 is	a	risk	of	arterial	 injury	 in	endoscopic	endonasal	
surgery	 which,	 depending	 on	 the	 approach,	 is	 in	 the	 order	 of	 0.5%-9%.	 Valentine	 and	
Wormald	 have	 developed	 a	 sheep	model	 of	 carotid	 artery	 injury(117).	Merino	 sheep	 are	
anaesthetised	and	undergo	a	midline	neck	dissection.	The	carotid	 is	 identified	 in	 the	neck	
and	 a	 length	 approximately	 20cm	 is	 freed.	 A	 functional	 endoscopic	 sinus	 surgery	 (FESS)	
training	device	 is	applied	to	the	carotid	and	surgeons	can	drill	 the	posterior	plastic	wall	to	
expose	 the	 carotid	 itself.	 The	 carotid	 is	 then	 sharply	 incised	 to	 create	 a	 model	 of	





view	of	surgical	 training,	 this	 is	a	valuable	model	 that	allows	surgeons	 to	be	exposed	to	a	
relatively	 rare	 and	potentially	 fatal	 event	 and	equip	 them	with	 the	 skills	 required	 to	deal	




or	 challenging	 situation.	 Contemporaneous	 questionnaires	 are	 obviously	 tempered	
somewhat	by	the	surgeon	filling	it	out	after	having	dealt	with	the	situation	and	being	aware	
of	the	outcome.	They	are	also	somewhat	subjective.	This	 is	not	entirely	inappropriate	as	a	
tool	 for	research	as	the	stress	response	has	a	psychological	component	to	 it	however	 it	 is	
subject	to	biases	and	a	relative	and	subjective	grading	system(484).	The	ideal	method	would	





to	 the	 assessment	 of	 stress	 on	 performance(519).	 Multiple	 studies	 have	 video-taped	
surgeons	in	training	as	part	of	simulation	exercises.	These	have	the	dual	purpose	of	allowing	
surgeons	 to	watch	 themselves	 and	 pick	 up	 any	 deficits	 in	 communication	 or	 non-surgical	
technical	skills	that	may	occur	whilst	also	allowing	independent	surgeons	and	psychologists	
to	rate	communication	skills	outside	of	the	scenario.	Stress	can	have	a	negative	impact	upon	











































































































































































































































































The	peptide	chosen	was	RADA-16	(Arg - Ala - Asp - Ala - Arg - Ala - Asp - Ala - Arg - Ala - Asp - Ala - Arg - 












































































































































































































































































































































Muscle		 850.3	 103.6	 593.1	 1108	
Anastoclip	 249.1	 177.2	 112.9	 385.3	
Tachosil	 124	 50.5	 70.9	 177	
Evicel	 79.8	 10.3	 69	 90.6	












































Muscle		 928	 209.8	 406.7	 1449	
Anastoclip	 146.2	 197.7	 17.4	 298.2	
Tachosil	 281.7	 166.5	 106.9	 456.4	
Evicel	 150.8	 43.1	 105.5	 196.1	






















































































Tachosil	 [Baxter]	 is	 a	 topical	 sealant	 patch	 (9.5x4.8cm)	 that	 consists	 of	 human	 fibrinogen	
(3.6	to	7.4	mg	(5.5	mg)	per	cm2	and	human	thrombin	(1.3	to	2.7	Units	(2.0	U)	per	cm2)(291)	
coated	 onto	 an	 equine-derived	 collagen	 sponge.	 It	 is	 thought	 to	 work	 by	 activation	 of	
fibrinogen	 into	 fibrin	monomers	with	subsequent	polymerization.	The	 fibrin	polymers	and	
platelet	 activation	 lead	 to	 subsequent	 activation	 of	 the	 coagulation	 cascade	with	 further	
adherence	 to	 the	wound	surface	via	 further	 thrombin	mediated	 fibrin	polymerization	and	
conglutination	 of	 the	 patch’s	 collagen	 matrix	 and	 the	 wound	 surface,	 forming	 a	 tight	
seal(242,	243,	247,	248,	293).	Tachosil	is	indicated	for	use	in	cardiac	and	hepatic	surgery	as	
an	adjunct	to	haemostasis	where	it	is	placed	as	a	sheet	upon	the	bleeding	surface(291).	The	
literature	 is	 replete	with	 case	 reports	 and	 small	 series	 of	 novel	 use.	 Several	 cardiac	 case	
studies	 report	 its	use	 to	 seal	 ventricular	bleeding	post	 infarction	and	 rupture	and	at	 least	
one	 case	of	 its	 use	 to	 seal	 a	 high	pressure	 ruptured	 coronary	 artery(296-299).	 It	 has	 also	
been	trialed	to	prevent	the	development	of	pericardial	adhesions	post	cardiac	surgery(300,	
301),	 been	 used	 in	 swine	 liver	 and	 spleen	 injury	 models(299,	 302-304),	 gynaecological	












of	 thrombosis	 of	 the	 sinus	 as	 a	 result	 of	 its	 use(293).	 Whilst	 the	 incidence	 of	 the	
development	 of	 antibodies	 to	 the	 human	 fibrin	 and	 thrombin	 is	 less	 than	 1%,	 a	 paper	
reporting	the	use	of	Tachosil	in	a	hepatic	haemorrhage	model	reported	that	the	incidence	of	
development	of	antibodies	to	equine	collagen	was	26%(293,	313).	This	did	not	result	in	any	




frozen	 solution	 provided	 in	 separate	 vials	 which	 are	 mixed	 in	 a	 sterile	 applicator.	 It	 is	
dripped	or	sprayed	onto	the	wound.	In	a	prospective	randomised	controlled	trial,	Evicel	was	
compared	 with	 manual	 compression	 only	 in	 patients	 undergoing	 end	 to	 side	 femoral	 or	
upper	 extremity	 arterial	 anastomoses(245).	 Evicel	 was	 significantly	 more	 effective	 at	
achieving	 haemostasis	 than	 manual	 compression	 alone	 at	 the	 4-minute	 mark	 (85%	 vs	




































































































































































































































































































































































major	arterial	hemorrhage	 to	 stop	bleeding.	The	mechanism	of	 this	 is	not	yet	 clear	but	 is	
thought	to	involve	the	formation	of	a	platelet	plug,	that	seals	the	vessel	wall	defect	but	still	
allows	ongoing	blood	flow	to	the	brain.		
Methods:	 This	 study	 uses	 flow	 cytometry	 to	 attempt	 to	 replicate	 the	 in	 vivo	 actions	 of	
crushed	muscle	on	platelets	in	whole	blood.	It	compares	the	ratio	of	activation	of	platelets	
exposed	 to	 crushed	 and	 uncrushed	muscle	 supernatant	 in	 control	 patients	 and	 those	 on	
antiplatelet	agents.		
Results:	Crushed	muscle	activated	platelets	to	a	higher	degree	than	uncrushed	muscle.	This	
ratio	 was	 5.18	 times	 greater	 in	 control	 blood	 (P=0.002),	 6.53	 times	 greater	 in	 aspirin-
exposed	blood	(P<0.0001)	and	9.4	times	greater	in	clopidogrel	exposed	blood	(P<0.0001).		
Conclusion:	 Crushed	 muscle	 caused	 a	 consistently	 increased	 ratio	 of	 platelet	 activation	





Crushed	autologous	muscle	 is	 a	 known	adjunct	 to	major	 arterial	 hemorrhage	 control	 in	 a	









injuries	 results	 in	 decreased	 blood	 volume	 loss	 and	 faster	 time-to-hemostasis	 when	
compared	 with	 chitosan	 patches	 and	 surgical	 clips	 in	 pre-clinical	 models(117-120,	 122).	
There	 are	 a	 number	 of	 case	 reports	 of	 its	 use	 in	 potentially	 life-threatening	 carotid	
injury(130,	 142,	 167,	 532).	 The	 mechanism	 for	 this	 hemostatic	 effect	 is	 unknown.	 It	 is	
thought	 that	 crushed	 muscle	 releases	 factors	 that	 induce	 platelet	 activation	 and	





demonstrated	 significantly	 increased	 amounts	 of	 platelet	 aggregation	 with	 increasing	
concentrations	 of	 muscle	 supernatant	 (ranging	 from	 0.1mg/ml	 to	 0.8mg/ml)(145).	 Flow	
cytometry	provides	a	better	picture	of	 in	vivo	platelet	activity	as	 it	 analyses	whole	blood.	







Hospital,	 Adelaide,	 Australia.	 All	 patients	 provided	 informed	 written	 consent	 prior	 to	
enrollment.	Blood	specimens	were	prospectively	collected	from	30	patients.	Patients	were	
divided	 into	 those	 not	 taking	 antiplatelet	medications	 for	 at	 least	 three	months(controls)	





event	 in	 the	 previous	 3	 months).	 After	 discarding	 the	 first	 3ml	 of	 blood,	 samples	 were	












50µl	 of	muscle	 supernatant,	 adenosine	diphosphate	 (ADP)	or	PBS	was	 incubated	at	 room	
temperature	for	5	minutes	with	0.45ml	of	blood	per	sample.	Samples	were	then	stained	for	
15	 minutes	 at	 room	 temperature	 with	 CD62	 (APC,	 clone	 AK-4)	 to	 define	 unactivated	
platelets	and	PAC-1	(AF488	clone	PAC-1)	to	determine	activated	platelets.	(Becton	Dickinson	
Biosciences,	 San	 Jose,	 CA,	 USA).	 Gates	 were	 based	 on	 Fluorescence	 minus	 one	 (FMO)	
Controls.	(Fig.	1).	
	
We	 sought	 to	 identify	 whether	 exposure	 to	 crushed	 and	 uncrushed	 muscle	 supernatant	
results	 in	direct	platelet	activation,	using	flow	cytometry	to	examine	whole	blood	exposed	
to	 each	 of	 these.	 In	 order	 to	 determine	 the	 potential	 inhibitory	 effect	 of	 commonly	








mean	 percentage	 activation	 in	 each	 blood	 group	 between	 each	 hemostatic	 agent	 were	














clopidogrel-blood.	 ADP	was	 used	 as	 a	 positive	 control.	 ADP	 exposure	 resulted	 in	 a	mean	
platelet	 activation	 of	 20.08%	 (95%CI	 9.21-30.95)	 in	 control	 blood,	 45.46%	 (95%CI	 16.80-
74.12)	 in	 aspirin-exposed	 blood	 and	 36.68%	 (95%CI	 14.03-63.33)	 in	 clopidogrel-exposed	
blood.	 ‘Unactivated’	exposure	where	blood	was	not	exposed	 to	any	hemostatic	agent	but	
just	labelled	with	antibodies	gave	a	mean	platelet	activation	of	0.78%	(95%CI	0.40-1.16)	in	












































































Group Agent 1 Agent 2 Mean ratio (95% CI) p 
Aspirin Crushed Uncrushed 6.53(3.00-14.22) <0.0001 
Clopidogrel Crushed Uncrushed 9.40(4.30-20.53) <0.0001 












Group Presentation Mean(95%CI) Median(95% CI) 
Aspirin ADP 45.46(16.80-74.12) 54.50(7.4-68.0) 
Aspirin Crushed 31.38(14.22-48.54) 27.40(0.2-62.0) 
Aspirin Unactivated 15.94(4.80-27.08) 11.90(0.3-36.8) 
Aspirin Uncrushed 5.84(0.31-11.37) 1.90(0.4-23.4) 
Clopidogrel ADP 38.68(14.03-63.33) 46.60(5.2-54.6) 
Clopidogrel Crushed 26.08(16.02-36.14) 25.85(5.5-43.5) 
Clopidogrel Unactivated 10.01(2.25-17.77) 7.55(0.0-28.4) 
Clopidogrel Uncrushed 4.67(0.40-8.94) 2.45(0.1-19.5) 
Normal ADP 20.08(9.21-30.95) 22.00(1.1-52.3) 
Normal Crushed 6.63(0.55-12.71) 3.65(0.2-28.4) 
Normal Unactivated 0.78(0.40-1.16) 0.75(0.0-1.9) 



















Figure 3. Percentage of activated platelets (PAC1 +) out of total platelets (CD42+), in (A) 
Control patients, (B) patients on Aspirin and (C) patients on Clopidogrel in crushed, 
uncrushed, ADP activated and un-activated patient samples. Medians with interquartile 




































































































































































































































































































































































































































































































































































































































































































































































































































hemorrhage	 to	 stop	 bleeding.	 The	 mechanism	 of	 this	 is	 not	 yet	 clear	 but	 is	 thought	 to	
involve	 the	 formation	 of	 a	 platelet	 plug,	 that	 seals	 the	 vessel	 wall	 defect	 but	 still	 allows	
ongoing	blood	flow	to	the	brain.	Chapter	4	describes	a	flow	cytometry	study,	published	in	
2017,	 designed	 to	 replicate	 the	 in	 vivo	 actions	 of	 crushed	 muscle	 on	 platelets	 in	 whole	
blood.	 It	 compared	 the	 ratio	of	 activation	of	platelets	exposed	 to	 crushed	and	uncrushed	
muscle	 supernatant	 in	 control	 patients	 and	 those	 on	 antiplatelet	 agents.	 This	 study	
demonstrated	 that	 crushed	muscle	 activated	platelets	 to	 a	higher	degree	 than	uncrushed	
muscle.	This	ratio	was	5.18	times	greater	 in	control	blood	(P=0.002),	6.53	times	greater	 in	
aspirin-exposed	 blood	 (P<0.0001)	 and	 9.4	 times	 greater	 in	 clopidogrel	 exposed	 blood	
(P<0.0001).	 Crushed	 muscle	 caused	 a	 consistently	 increased	 ratio	 of	 platelet	 activation	













































This	 thesis	 describes	 novel	 techniques	 for	 large	 vessel,	 high	 pressure,	 high	 volume	




































Management of Internal Carotid 
Artery Injury
Introduction
Internal carotid artery (ICA) bleeding in endoscopic endonasal surgery is one of the most feared 
complications. There are a wide range of pathologies that involve the major vessels of the skull base, 
which include sinus, nasopharyngeal, neural and dural-based tumors, bony skull lesions, cavernous 
sinus pathologies, and, importantly, vascular aneurysms and malformations.1-3 The skull base is 
an anatomically constrained area with brain parenchyma, neural and vascular structures, bony 
prominences and canals, and dural reflections that make it one of the most difficult areas in which 
a surgeon can operate. In addition to this, with a major vascular injury and the level of difficulty 
increases enormously as does the potential for a poor outcome for the patient.
Incidence
The incidence of major vessel injury in uncomplicated midline endoscopic skull base surgery varies 
in the literature but ranges somewhere between 0.58 and 1.1%.4-9 This is in contrast to the much 
lower rate in endoscopic sinus surgery (<0.25%) in which the sphenoid sinus is either not entered or 
not drilled extensively.7 These rates are much higher in the case of extended endoscopic approaches 
(EEAs) in which the instruments and endoscope may come into more direct contact with the carotid 
artery or require more extensive bone removal. These EEAs generally extend the surgical corridor 
more rostral or caudal and may, through the use of angled scopes also extend the boundaries of the 
approach laterally. Couldwell et al, Cavallo et al, and Gardner et al report rates of 5 to 9% in series of 
craniopharyngiomas, chordomas, and chondrosarcomas, which, by virtue of their location and tumor 
consistency, invariably require more bone removal or dissection.4-7, 10-13 Surgeons who have been 
involved with more than 500 transsphenoidal approaches are thought to have a greater than 50% 
chance of having seen a carotid artery injury.14 Given the increasing use of endoscopic transsphenoidal 
surgery to access more complex pathologies, it is reasonable to assume that rates will only increase 
despite the author’s knowledge of predisposing factors.
Initial Planning and Management
The most important initial management step occurs before the operation begins and requires that the 
surgeon be proactive in assessing the likelihood of the occurrence of injury. Tumors that encase the 
carotid, or are at least adherent in a plane of more than 120 degrees, and those tumors in which the 
surgical intent is curative, total resection are at a much higher risk. These cases should be discussed in 
a multidisciplinary meeting with skull base otolaryngologists, skull base neurosurgeons, radiologists, 






the value of developing a team-based approach to skull-base surgery, and that extended endonasal 
cases should not be attempted before developing a collaborative team able within the institution. 
Additionally, team-based training in vascular injuries courses on animal models (Figs. 12.1, 12.2), 
such as that developed by Valentine and Wormald, is invaluable and allows surgical teams to practice 
managing this stressful scenario.4-6
Fig. 12.1 Endoscopic trainer utilized sheep carotid artery injury model.
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Risk Factors
It is important to review the preoperative imaging closely to determine whether there are any 
predisposing factors that may increase the risk of ICA injury and allow modifications to surgical 
technique at any predetermined “danger points.” These factors may be divided into anatomical factors, 
tumor factors, and patient factors.
Anatomical Factors
The wall of the sphenoid sinus is deficient in 4 to 22% of cases, leaving only the mucosa or dura to 
surround the carotid. Even if present, the wall should not be considered thick enough to protect the 
artery from the drill or other instruments.15 Bone windows on preoperative computed tomography 
(CT) may assist with this but should not be relied on.
The carotids may also deviate toward the midline. The ICAs are usually at least 12 mm apart but 
have been described as close together as 4 mm in their cavernous segment and, rarely, even touching 
each other. These so-called “kissing carotids” have been considered as having contributed to ICA injury 
in several case reports.16 Magnetic resonance angiography (MRA) may be performed, but even on plain 
magnetic resonance imaging (MRI) flow voids may be seen on axial slices and the distance between 
these measured.
There may be bony septations and spicules within the sphenoid and cavernous sinuses that, while 
not being dangerous in themselves, may either require the use of instrumentation to remove with 
consequent risk of ICA injury by either bone fragments or the instruments themselves.
Cavernous segment ICA aneurysms make up to 12% of total intracranial aneurysms in some case 
series and require the surgeon to carefully plan any endoscopic approach.17-20 It is advisable to consider 
treating these prior to attempting any endoscopic endonasal skull base approaches.21-23 These may 
be treated with flow diverting stents with or without coil insertion into the fundus; however, it is 
important to recognize that this will require the patient to take antiplatelet therapy for at least 3 to 6 
months post stent insertion that may factor into further surgical planning.
Tumor Factors
Tumors may themselves adhere to the ICA, and any extension into the cavernous sinus should be 
approached with caution, especially if this extends greater than 120 degrees around the ICA. There is 
a risk of tumor adherence to the ICA. This not only predisposes the ICA to injury when the tumor is 
dissected off the carotid, but this dissection may result in vasospasm as the carotid is handled.24 This 
may manifest as neurologic injury or as elevated blood pressure as the patient attempts to maintain 
cerebral perfusion pressure with impaired autoregulation.
The tumor size is an independent risk factor. Tumors that require extensive bone removal for 
exposure will tend to require exposure of more of the ICA.
There also appears to be an increased risk of carotid injury with pituitary tumors secreting growth 
hormone or adrenocorticotrophic-releasing hormone (ACTH).25,26 This may not be only due to tumor 
size or invasion but also due to as yet undefined influences of insulin-like growth factor 1 (IGF-1) or 
cortisol on the arterial wall.7
Patient Factors
Previous transsphenoidal surgery may result in aberrant anatomy and adhesions. It may also be 
difficult to ascertain the precise amount of anatomical disruption and bone removal that has previously 
occurred. Previous radiation to the region may result in scarring, adhesions, or more friable vessels. 
Bromocriptine therapy appears to increase the risk of ICA injury, possibly because of adhesions and 
fibrosis, and acromegaly patients have a tendency toward more ectatic and tortuous carotid arteries.7,24 







Ideally factors such as anatomical variation or the possibility of tumor erosion into the artery or 
cavernous sinus will have alerted the surgeon to the danger of injury to the carotid artery; however, this 
is not always possible or indeed reliable.27,28 The entire surgical team must be alert to the possibility of 
injury. A preoperative briefing involving all staff that identifies the risks involved and the plan, should 
such an injury occur, is a highly valuable step. The patient should always be cross-matched and blood 
available, especially in more extended endonasal approaches. Anesthetic staff should be aware of the 
possibility of ICA injury and have a plan in place in the event that it occurs. Large-bore IV access and 
invasive arterial monitoring should be considered prior to it being required. Neuronavigation should 
be utilized as, while it does not replace a thorough knowledge of anatomy, it gives the surgeon greater 
confidence in identifying anatomical structures intraoperatively. A Doppler ultrasound device with an 
angled probe may also be useful to identify the ICA intraoperatively.
Theater staff should have patties, gauze, and oxidized cellulose (authors prefer Surgicel snow 
[Ethicon, NJ, United States] for its absorptive capacity) on the setup for all cases and the endoscope 
should have a lens-cleaning system attached. There should be two 10F suction devices on the setup. 
These suction devices should be checked to ensure that they work and do not require changing immedi-
ately prior to any bone removal and at regular intervals. Authors advocate the use of blunt instru ments, 
such as suction freer dissectors and pituitary ring curettes, when working adjacent to the ICA and that 
bone removal should take place with diamond rather than cutting burrs. It may also be advisable that 
when using Kerrison’s punch, a twisting or pulling motion is not used, but that the sharp edges of the 
instrument are allowed to completely transect the bone before removal.24 These should all be ready on 
the instrument tray at the commencement of the case. The patient should be draped to allow access to 
the lateral thigh or abdomen for muscle harvesting as required. It may also be advisable for the angio-
graphy service to be made aware that the operation is planned in case they are required post any injury.
Injury Types
It is important to be aware of the different injury types that are seen in injury to the carotid vessel. 
These range from linear incisions to stellate or large wall defects caused by Kerrison-type punches or 
high-speed drill injury. While initial management and resuscitation is the same, the likelihood that 
different techniques may work varies accordingly and decision making should reflect this.8
Table12.1 Factors contributing to increased risk of internal carotid artery injury
Anatomical Sphenoid wall defect
Carotid proximity
Bony septations and spicules
Cavernous segment ICA aneurysm
Tumor Encasement of ICA
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Initial Management
The immediate management of injury to the carotid artery in endoscopic surgery is a team-centered 
approach involving coordination between nursing, anesthetic, and surgical staff.27 Communication with 
the anesthetic staff early is vital and the staff should immediately begin volume resuscitation of the 
patient before their hemodynamic parameters are affected. It is important to maintain normotension 
or even mild hypertension. Cerebral perfusion is vital to maintain despite the temptation to lower the 
blood pressure to assist hemostasis. Theater staff should check the suction to ensure that the bag is 
not becoming full, which may lead to a stoppage just when it is required the most. Theater staff should 
also activate the on-call angiography team.
ICA injury is only possible to manage with a “two-surgeon, four-hand” approach. A second surgeon’s 
assistance must be immediately sought if they are not already in the room. A third surgeon may also 
be utilized to harvest muscle from the abdomen or lateral thigh. Visualization is key to management 
and the endoscope lens must remain free of blood. To achieve this, the second surgeon introduces the 
suction down the side with most bleeding, clearing the majority of the blood and allowing the first 
surgeon to advance the second suction just ahead of the endoscope down the other nostril and into the 
surgical field. The second surgeon’s suction is used to direct the blood flow away from the endoscope 
lens. Once the site of bleeding is visualized, the second surgeon moves the suction directly over the 
bleeding point of the vessel. This suction is hovered over the bleed point collecting all the blood from 
the injury. The need to have space in the surgical field for both surgeons to operate is important so 
that when the surgical approach to the lesion is planned creation of such space should be part of the 
approach. Routine removal of the posterior septum and floor of sphenoid to create a single posterior 
cavity is helpful as the surgeons may use both the nostrils to pass instruments and the endoscope.
Once visualization has been achieved, pressure can be applied to the bleeding point with patties, 
gauze, or Surgicel snow as a temporizing measure. It is tempting to pack the entire nasopharynx in 
an attempt to stop the bleeding, but this should be avoided as much as possible as it impedes access 
to the bleeding point. Depending on the point reached in the operation, this practice may stop the 
bleeding from exiting the nose, but blood may be directed intracranially with detrimental results. 
Overpacking may also completely occlude the ICA and any other vessels exposed with potentially 
devastating results. In theory, acute unilateral ICA blood flow disruption should result in contralateral 
ICA and vertebral artery flow reaching the hemispheres through the circle of Willis. In practice, 
however, this is highly variable. Techniques to control hemorrhage in endoscopic skull base surgery 
must take this factor into account and maintain patency of flow through the ICA as much as possible. 
The evidence from neurosurgical literature regarding the temporary proximal clipping of feeding 
vessels indicates that interruption to the blood supply of less than 3 to 5 minutes is generally well 
tolerated with the brain likely deriving oxygen and glucose from collateral perfusion; however, longer 
times risk permanent neuron and astrocyte death.29-31 Care should also be taken when extrapolating 
these data to entire anterior circulation or whole hemisphere models that would occur with sudden, 
complete ICA occlusion.
Options for Hemostasis
Traditionally, 1 to 2 cm3 of the muscle has been harvested from the abdomen or thigh. This is crushed 
between two hard surfaces, placed over the bleeding point, and held in place for at least 5 to 7 minutes 
(although this may take up to 12 minutes to adhere).4-7 It is important to hold this in place with 
sufficient pressure to stem the bleeding but not to completely occlude the artery (Fig. 12.3). The 
crushed muscle is thought to activate a platelet/fibrin plug that seals the artery while the high flow 
within the lumen maintains patency of the parent vessel.32 No attempt should be made to remove 
the muscle once hemostasis has been achieved. This muscle patch should be reinforced with oxidized 
cellulose, and if the carotid injury is within the sphenoid sinus, a pedicled septal flap is placed over 






If the lesion is in the sphenoid, nasal packing may then be placed; however, it is important that this is 
not packed too tightly as this may occlude distal ICA flow. This method is suitable for both linear and 
stellate or jagged-type injuries.
If the injury is clearly able to be visualized, accessed with instruments, direct vessel closure may 
be attempted. This is usually more applicable for linear injuries. Padhye et al have shown in a sheep 
model of hemorrhage that a curved T2 aneurysm clip may be applied to the wall of the vessel without 
occluding the lumen.9 Direct closure may also be achieved with a “pincer”-type metal clip (AnastoClip, 
LeMaitre Vascular, MA, United States). The vessel walls are held together by a Wormald endovascular 
clamp or aneurysm clip and the AnastoClips applied sequentially along the injury (Fig. 12.4).
Current and Future Studies in Animal Models
There are several other commercially available products that have been trialed with varying degrees 
of success. In general, the authors have found that the high-flow/high-pressure bleed will tend to 
wash away thrombin-based powders such as Floseal (Baxter, IL, United States) or Surgiflow (Ethicon, 
NJ, United States) and fibrin/thrombin glues. Animals trials within the author’s department have 
demonstrated that it is possible to stop carotid bleeding with fibrin/thrombin glue, however, only if 
the initial blood jet is able to be controlled with Surgicel snow and the glue is then able to be applied 
Fig. 12.3 Hemorrhage control in a sheep model. (a) Blood jet from internal carotid artery. (b) Sucker in 
contralateral nostril used to direct flow away from endoscope lens. (c) Crushed muscle patch being applied. 
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without being washed away. Pressure is applied with instruments for 5 to 7 minutes. The authors do 
not yet have data of the long-term efficacy of this or the rate of pseudoaneurysm formation. Another 
option is human-derived fibrin/thrombin embedded in a collagen-based patch such as Tachosil 
(Baxter). This has an active and nonactive side, and the authors have found it useful to fold this over 
upon itself so that all sides are effectively hemostatic. Again, the authors have found this to work in an 
animal model but, as yet, have no long-term data of its efficacy or pseudoaneurysm formation.
Bipolar cautery devices have been designed specifically for endoscopic endonasal surgery and 
attempts have been made to use this technique on carotid injury.33 While this may work for smaller 
bleeds, there is a risk of the cautery device becoming adherent to the bleeding vessel with subsequent 
tearing when attempts are made to remove the instrument. There is some experimental evidence to 
suggest a higher rate of secondary bleeds and complete vessel occlusion than other methods and the 
authors do not recommend its use in ICA bleeding.24
Endovascular Control
If hemostasis is not able to be achieved with these methods, endovascular intervention may be 
urgently required to occlude the ICA. It is important that endoscopic techniques are attempted first 
as endovascular intervention tends to result in artery sacrifice. Balloon or coil occlusion should be 
performed at the site of injury to prevent ongoing hemorrhage from antegrade or retrograde filling. It 
is also important to avoid balloon or coil migration and subsequent occlusion of the ophthalmic artery 
(a complication discussed later). It is important to emphasize that endovascular intervention at this 
point is a lifesaving procedure and that a presacrifice balloon test occlusion is not likely to change 
management at this stage, in contrast to the elective setting. Flowchart 12.1 shows hemorrhage 
control in ICA injury.
Postoperative Management
Once hemostasis has been achieved, the patient should undergo a formal angiogram to determine 
perfusion through the site of injury, ongoing bleeding, and whether a dissection, pseudoaneurysm, 
or carotid-cavernous fistula has formed.27 It is advisable to perform this immediately under the same 
anesthetic to avoid blood pressure fluctuation or Valsalva being performed by the patient on emergence 
and extubation, which may potentially cause the patch to “blow off” the vessel. The surgeon should 
attend the initial formal angiogram to determine whether the ICA is patent, especially if large amounts 
of nasal packing have been left in situ. If this is “overpacked,” the patient may need some of this 
removed to allow distal flow in the ICA. It is important to note that while the authors have discussed 
the obvious and immediate ICA bleed, a smaller, unrecognized injury may occur and manifest in the 
weeks or months following surgery.
a b c
Fig. 12.4 (a) Wormald vascular clamp across carotid laceration in a sheep model of hemorrhage. 






If unable to control, do 
nasal packing and transfer 
it urgently to angiogram
suite for ICA occlusion
Immediate post-operative 
angiogram after transfer 
to ICU and extubate in 
controlled fashion
Repeat angiogram at  
6 weeks and 1 year post-
operatively
The decision to extubate the patient depends on whether any vascular anomaly is discovered at 
the initial postoperative angiogram. If none is discovered, a reasonable option is to wake the patient 
slowly in intensive care unit (ICU), avoiding blood pressure fluctuations, and ensuring that cerebral 
perfusion is maintained.
If an arterial wall injury such as a dissection flap is seen on formal angiogram, it is reasonable to 
assume that the intima has been disrupted with potential for thrombosis and subsequent embolism 
to occur. Some authors advocate intravenous heparin administration at the time of injury.27 Much of 
the rationale behind this has been extrapolated from stroke literature, which tends to limit external 
validity when applying these data to the ICA injury patient population. The Cervical Artery Dissection 
in Stroke Study (CADISS) trial, designed to determine the optimal treatment for carotid dissection, was 
unable to recommend whether antiplatelet agents or anticoagulant agents should be used.34 Author’s 
practice has been to wait until the immediate postoperative angiogram to make a judgment regarding 
the risks and benefits of anticoagulation at this point.
Complications
After an ICA injury there is the potential for the development of a pseudoaneurysm. The putative 
mechanism of development is damage to the vessel in the initial phase with subsequent arterial 
pulsations forcing blood between layers (sometimes known as false aneurysm) or, more commonly 
in this context, between the damaged vessel and the patch or packing that has been applied. 
Surgeon Actions
•• Sucker down
•• Ipsilateral nostril 
•• Camera down
•• Contralateral 
•• Second sucker hovers 
•• Over bleed
•• Pattie or surgical 
•• Snow to temporize 




•• Early blood plasma and 
platelet replacement
•• Ensure adequate access
Theater Staff Actions
•• Check suckers and 
equipment 
•• Call angiogram team and on 
call interventional radiologist
Notify theater of ICA injury and call second surgeon
Flowchart 12.1 Hemorrhage control in internal carotid artery injury. ICA, internal carotid artery.
Preoperative brief with all theater team members
Preoperative planning in multi-disciplinary 
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This grows larger over time as the systolic pressure forces further tracking of blood along this dissection 
layer.35 The most common etiology worldwide is in penetrating cranial trauma such as stabbing or 
shrapnel/bullet wounds and the majority of the literature supporting treatment is extrapolated from 
this.36,37 Post-ICA injury, it is generally considered that the incidence of subsequent pseudoaneurysm 
development is in the order of 10 to 35%; however, some series report up to 66%.8,11,38,39 This is partly 
a function of the low case numbers in each case series reported and partly because no reliable animal 
model of this exists. A pooled analysis of case series would seem to indicate that a reasonable estimate 
would make the rate somewhere between 10 and 35% across all patients with a patent ICA.38 The 
formal angiogram should be repeated; authors advocate for this at 1 week postoperatively and then 
again at 6 weeks and 1 year postoperatively.8,9,40-43
The treatment of pseudoaneurysm is dependant on size, location, and whether it has ruptured prior 
to treatment. The pseudoaneurysm is usually coiled and/or the artery stented as first-line management 
(Fig. 12.5). Given that even a balloon test occlusion cannot reliably predict a patient’s reliance on 
blood flow from a particular carotid artery, consideration should be given to preserving the carotid, 
if possible.44 It is possible to perform an endovascular sacrifice of the carotid artery by completely 
occluding it with coils; however, this leaves the patient at risk of developing an infarction distal to this.27 
The most common intervention is stenting of the parent vessel. Direct open repair and remodeling can 
be considered but is generally not possible in the cavernous segment of the carotid.9,42,43,45-50 It may 
also be possible to use a flow-diverting stent that directs flow beyond the pseudoaneurysm and causes 
stasis and subsequent thrombosis within the aneurysm.45 It is important to be aware of the location of 
the ophthalmic artery in relation to the pseudoaneurysm. The ophthalmic artery typically leaves the 
ICA a few millimeters beyond any injury to the cavernous segment and stent migration may occur, 
occluding this artery and resulting in potential blindness or even death. Additionally, rates of stroke 
following carotid stenting can be as high as 4.5% in the first 30 days and patients are generally treated 
with dual-antiplatelet agents (aspirin and clopidogrel) or similar agents that may delay or preclude 
further surgery.22,23,51-54
Another vascular complication is the development of a carotid—cavernous fistula. In this situation, 
arterial blood escapes from a defect in the ICA and enters directly into the venous channels of the 
cavernous sinus. Symptoms and signs of this include proptosis, chemosis, conjunctival injection, 
ocular bruit, blindness due to venous hypertension, ophthalmoplegia due to cranial nerve defects, 
pulsatile tinnitus, venous infarct of the cortex, and pain.55 The initial imaging is often CT or MRI that 
demonstrate characteristic features of proptosis and “corkscrewing” of engorged vessels; however, 
diagnosis requires formal angiogram and demonstration of early venous filling as blood exits the 
ICA.55-58 Treatment is performed via endovascular approach with obliteration of the fistula via coils, 
glue, stenting, or combination of these.40,55,56,58-60
Fig. 12.5 Pseudoaneurysm post internal carotid artery injury. (a) Initial angiogram with no aneurysm. 








ICA injury is a potentially devastating complication of endoscopic endonasal surgery. It is crucial to 
have a plan in place before this potentially disastrous situation occurs. Good communication and 
teamwork is vital to ensure that the situation is rapidly brought under control. It is helpful to have 
a trained team for this eventuality and ensure that team members’ roles are clearly defined before 
this situation is encountered. Training has been shown to improve the outcome for injuries managed 
by surgeons subsequent to training.9,24 The muscle patch is certainly the simplest and most studied 
hemostatic material utilized in this setting; however, if the injury is able to be both visualized and 
accessed by instruments, direct laceration closure with AnastoClip (LeMaitre vascular) or a curved T2 
aneurysm clip may be attempted. It is important that whatever technique is used, that vessel lumen 
patency is maintained and ongoing flow to allow distal perfusion of the brain occurs. Endovascular 
sacrifice of the vessel is the last resort and one that may potentially lead to neurologic deficit, even 
if one had performed a balloon test occlusion previously. It is important to realize that stopping the 
hemorrhage is merely the first step in the management of these patients and they will require ongoing 
angiographic follow-up to ensure that they do not develop pseudoaneurysm, carotid-cavernous 
fistulae, or have a delayed ICA rupture. It is crucial that endoscopic, endonasal skull base operations, 
even those that are considered comparatively simple, are performed by a dedicated skull base team 
and that all cases are discussed and individualized risk analysis is performed preoperatively.
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